Calypte - JETZT EINSTEIGEN? - 500 Beiträge pro Seite
eröffnet am 12.03.02 18:40:19 von
neuester Beitrag 16.03.02 18:08:43 von
neuester Beitrag 16.03.02 18:08:43 von
Beiträge: 49
ID: 564.731
ID: 564.731
Aufrufe heute: 0
Gesamt: 2.188
Gesamt: 2.188
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 53 Minuten | 2196 | |
| gestern 18:44 | 2107 | |
| vor 26 Minuten | 1825 | |
| gestern 17:20 | 1205 | |
| vor 43 Minuten | 942 | |
| vor 24 Minuten | 876 | |
| heute 07:56 | 848 | |
| vor 26 Minuten | 714 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.964,21 | +0,14 | 205 | |||
| 2. | 2. | 166,96 | -0,65 | 108 | |||
| 3. | 4. | 0,0164 | +0,61 | 62 | |||
| 4. | 3. | 8,6800 | +0,46 | 61 | |||
| 5. | 7. | 0,9000 | -10,00 | 54 | |||
| 6. | 6. | 2.301,18 | -0,11 | 38 | |||
| 7. | 14. | 6,1540 | -1,12 | 37 | |||
| 8. | 8. | 6,6440 | -0,06 | 36 |
Feedback
Hi Leute,
habe mich die letzten Tage mal ein wenig mit Calypte auseinandergesetzt. Was meint Ihr, ist jetzt der Zeitpunkt zum einsteigen?
Viel weiter runter kann es garantiert nicht mehr gehen, aber nach oben ist alles offen. Wenn der Wert ins rollen kommt, dann ist wohl kein halten mehr angesagt.
Bin auf Eure Meinungen gespannt...
Gruß
Stockhunter
habe mich die letzten Tage mal ein wenig mit Calypte auseinandergesetzt. Was meint Ihr, ist jetzt der Zeitpunkt zum einsteigen?
Viel weiter runter kann es garantiert nicht mehr gehen, aber nach oben ist alles offen. Wenn der Wert ins rollen kommt, dann ist wohl kein halten mehr angesagt.
Bin auf Eure Meinungen gespannt...
Gruß
Stockhunter
A rebroadcast of the Calypte presentation at The Wall Street Analyst Forum`s Institutional Investor Conference can be accessed from the company`s website at www.calypte.com through March 14, 2002.
Gruß Boersenkraehe
Gruß Boersenkraehe
@boersenkrähe
Kannst Du vielleicht den Link genauer angeben ?
Habe es nicht bei www.calypte.com gefunden.
Danke im voraus,
thorulte
Kannst Du vielleicht den Link genauer angeben ?
Habe es nicht bei www.calypte.com gefunden.
Danke im voraus,
thorulte
@thorulte
Ist alt, aber ich hatte mir den Termin auf Kalender geschrieben.
Bin gespannt was bis Freitag passiert!
Calypte Biomedical Presents At Wall Street Analyst Forum; Shares plans for future growth with analysts, portfolio managers at key New York conference
TUESDAY, FEBRUARY 19, 2002 12:57 PM
- BusinessWire
ALAMEDA, Calif., Feb 19, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (CALY) , a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, shared its plans for future growth with several dozen analysts and portfolio managers late last week at The Wall Street Analyst Forum`s Institutional Investor Conference in New York.
"By one global estimate," Calypte President & CEO Nancy Katz told the February 14 audience, "there are as many as 14,000 people a day contracting the AIDS virus. That`s roughly 100,000 new cases a week, or more than 350,000 a year, and that`s just for HIV-related illnesses," she said.
"Against that backdrop," Katz explained, "our mission of testing for the greater good takes on an even greater and more compelling significance. We think, and hope you`ll conclude, that Calypte is truly a company in the right place, at the right time, and worthy of your immediate consideration," she told the institutional investors.
The CEO, along with Executive Vice President and CFO Rick Brounstein, then reported that Calypte had just completed a record fourth quarter and full year, with revenues in 2001 more than doubling the year earlier period. Moreover, in 2001, said Brounstein, full year gross margin had approached break even, compared with a margin loss of $2.6MM (-79%) in 2000. In addition, he noted, while the first quarter of 2002 is not expected to be a record quarter sequentially, prospects for the current year indicate another period of significant growth.
Nancy Katz then defined milestones that investors could use to monitor the company`s progress in 2002. "Adoption of our tests by the World Health Organization, the enormous validation of having our tests now in use by the largest test provider in California, the growing acceptance of our test in the domestic insurance market, the potential for joint ventures offshore to manufacture and market, an expanded distribution system in China and active efforts to further expand other marketplaces, and at home to partner with a major drug firm to bring new disease tests to market - all of these events underscore the rapid and prominent advancement of Calypte Biomedical," Katz explained.
"We invite you to come on the journey with us...to become partners in our progress as shareholders, and to help us accelerate our mission to push back the frontiers of diagnostic testing - of testing for the greater good," the CEO said in closing.
A rebroadcast of the Calypte presentation at The Wall Street Analyst Forum`s Institutional Investor Conference can be accessed from the company`s website at www.calypte.com through March 14, 2002.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical
Gruß Boersenkraehe
Ohne vernünftigen Übersetzungsprogramm
Ist alt, aber ich hatte mir den Termin auf Kalender geschrieben.
Bin gespannt was bis Freitag passiert!
Calypte Biomedical Presents At Wall Street Analyst Forum; Shares plans for future growth with analysts, portfolio managers at key New York conference
TUESDAY, FEBRUARY 19, 2002 12:57 PM
- BusinessWire
ALAMEDA, Calif., Feb 19, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (CALY) , a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, shared its plans for future growth with several dozen analysts and portfolio managers late last week at The Wall Street Analyst Forum`s Institutional Investor Conference in New York.
"By one global estimate," Calypte President & CEO Nancy Katz told the February 14 audience, "there are as many as 14,000 people a day contracting the AIDS virus. That`s roughly 100,000 new cases a week, or more than 350,000 a year, and that`s just for HIV-related illnesses," she said.
"Against that backdrop," Katz explained, "our mission of testing for the greater good takes on an even greater and more compelling significance. We think, and hope you`ll conclude, that Calypte is truly a company in the right place, at the right time, and worthy of your immediate consideration," she told the institutional investors.
The CEO, along with Executive Vice President and CFO Rick Brounstein, then reported that Calypte had just completed a record fourth quarter and full year, with revenues in 2001 more than doubling the year earlier period. Moreover, in 2001, said Brounstein, full year gross margin had approached break even, compared with a margin loss of $2.6MM (-79%) in 2000. In addition, he noted, while the first quarter of 2002 is not expected to be a record quarter sequentially, prospects for the current year indicate another period of significant growth.
Nancy Katz then defined milestones that investors could use to monitor the company`s progress in 2002. "Adoption of our tests by the World Health Organization, the enormous validation of having our tests now in use by the largest test provider in California, the growing acceptance of our test in the domestic insurance market, the potential for joint ventures offshore to manufacture and market, an expanded distribution system in China and active efforts to further expand other marketplaces, and at home to partner with a major drug firm to bring new disease tests to market - all of these events underscore the rapid and prominent advancement of Calypte Biomedical," Katz explained.
"We invite you to come on the journey with us...to become partners in our progress as shareholders, and to help us accelerate our mission to push back the frontiers of diagnostic testing - of testing for the greater good," the CEO said in closing.
A rebroadcast of the Calypte presentation at The Wall Street Analyst Forum`s Institutional Investor Conference can be accessed from the company`s website at www.calypte.com through March 14, 2002.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2000 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical
Gruß Boersenkraehe
Ohne vernünftigen Übersetzungsprogramm
@stockhunter02
nimm dir die Zeit und lies dir die Caly-Threads durch
meiner Einschätzung nach gibt es mehr Gründe gegen ein Investment als für ein Investment. Du wirst aber schnell etwas anderes zu hören bekommen ;-)
nimm dir die Zeit und lies dir die Caly-Threads durch
meiner Einschätzung nach gibt es mehr Gründe gegen ein Investment als für ein Investment. Du wirst aber schnell etwas anderes zu hören bekommen ;-)
Trading Spotlight
Mein liebster 2 Bombi
Mein aller liebster 2 Bombi
Mein aller aller liebster 2 Bombi
Was spricht gegen ein Investment ?
Beste Grüß
Andy
P.S.
Achte auf SPAZ und die CeBit
Da kommt ein 1000 % Knaller
Mein aller liebster 2 Bombi
Mein aller aller liebster 2 Bombi
Was spricht gegen ein Investment ?
Beste Grüß
Andy
P.S.
Achte auf SPAZ und die CeBit
Da kommt ein 1000 % Knaller
Ok Andyschatz, du hast es nicht anders gewollt....
Investment Pro & Contra Calypte Biomedical
für Calypte spricht:
Sie haben ein fertiges Produkt, einen auf Urin basierenden HIV-Test der von der FDA zugelassen ist was in der Form (Urintest/FDA-Zulassung) einzigartig ist.
gegen Calypte spricht:
Der HIV-Test ist zwar in der Form (Urintest mit FDA-Zulassung) einzigartig, jedoch ist es nicht die einzigste Möglichkeit HIV zu diagnostizieren. Vor dem Calypte-Urintest gab es auch schon Möglichkeiten eine Infektion mit HIV nachzuweisen. Und diese gibt es immer noch !!! Des weiteren gibt es jede Menge Konkurrenz was das testen auf HIV betrifft. Neben dem Urintest von Calypte stehen nämlich jede Menge Bluttests u.a von Chiron/Bio-One usw. zur Auswahl.
So frag ich mich also, was hat also Calypte was andere nicht haben ????
FDA Zulassung des Urintests. Was ist die Wert ?? In China/Afrika/Asien/Süd und Mittelamerika (den „Epizentren“ von HIV ) im Grunde genommen gar nichts da der Einsatz des Tests dort nicht von der FDA-Zulassung abhängig ist. Die Zulassung der FDA ist „nur“ für die USA von übergeordneter Bedeutung andere Länder haben entweder keine (weiß nicht ob es in „3.Welt Ländern“ solche Zulassungsverfahren überhaupt gibt ! ) oder ihre eigenen Stellen wo das Produkt (Medikament) für einen Verkauf genehmigt werden muss. Ob nun eine FDA-Zulassung z.B für Europa unter umständen hilfreich ist lass ich mal ganz außer acht.
Wir haben ein Produkt (das nicht schlecht ist !!!) das verkauft werden muss um Gewinne zu erzielen, wem verkaufen wir es ?? Dem der es braucht, und wer ist das ?? Asien (China) Afrika, Südamerika..... OK, nehmen wir mal an das der Calypte Test 10€ kostet (weiß den genauen Preis im Augenblick nicht), gehen in eben diese Länder und versuchen ihn zu verkaufen. Spätestens hier sollte jedem klar werden das dies nicht so einfach ist! Und zwar aus dem einfachen Grund das 10€ teilweise in diesen Ländern ein ganzer Monatslohn bedeutet. In diesen Ländern wo der Test wohl am nötigsten gebraucht wird, geht es ums nackte überleben und da geht man nicht mal schnell in die Apotheke und holt sich ein HIV-Test. Fazit: Dort wo der größte Umsatz gemacht werden könnte fehlt das Geld, oder wer soll die Tests bezahlen ?? Die WHO ?? Die WHO war aus meiner sicht immer ein Hoffnungsschimmer was einen flächendeckenden Einsatz in solchen Gebieten Betrifft jedoch ist auch sie immer chronisch Pleite und auf fremde Gelder angewiesen. Und selbst wenn sie die Mittel haben bzw. bekommen sollten wer sagt dann das sie den Calypte –Test für dieses vorhaben wählen würden ??? So stelle ich also fest das in den „Wachstumsmärkten“ für Caly nicht all zu viel Wachstum zu generieren ist. Bleibt der Europäische und der US-Markt. Ich schaue mir dabei hier in Deutschland mal die Praxis an, wie wird hier getestet? Anhand von Blutproben wird das Blut in Labors auf HIV Erreger untersucht. Wann ? Bei normal sterblichen bei begründetem Verdacht oder wenn man z.B Blut spendet. Liegt hier eine mögliche Verwendung ??? Ich glaube nicht, da das Blut nicht explizit auf HIV untersucht wird sondern auf mehrere Faktoren. Es muss also so oder so in die Labors warum dann vorher noch mit einem Urintest auf HIV testen ?? Das gleiche gilt für Knochenmarkspender, da wird das Blut auch so nebenbei auf HIV untersucht. Bleiben also „nur“ noch die HIV – Fälle wo einzig und alleine nach einer HIV Infektion gesucht wird da es für viele andere Erkrankungen eh von Nöten ist Blut abzuzapfen. Wer käme da außer die Mädels vom Strich (ist zwar auch ein Wachstumsmarkt aber sicher nicht für Caly) noch in Frage ??? Versicherungen ???
Dieses Einsatzgebiet hab ich oft gehört und wusste nie ob ich darüber lachen soll oder ob es mich schockieren sollte. Der Versicherungsvertreter der mir sagt ich muss einen HIV Test machen bevor er mich versichert den werfe ich gleich wieder raus !!! Und ich glaube auch nicht das so etwas jemals auf einer gesetzlichen Grundlage geschehen würde, oder wird !!!
So schrumpft der Markt für Calypte immer mehr zusammen und wenn wir nun mal annehmen der Calyppte Test währe so einfach wie ein Schwangerschaftstest (was er meines Wissens nicht ist) was bleibt dann noch ???? Immer noch genug Menschen, aber warum sollten die den Calypte Test wählen ???
Nach all diesen Dingen blieb für mich eine Firma die ständig ums Überleben kämpft und schon das ein oder andere mal fast Pleite war. Eine Aktie mit sehr sehr dünnen Umsätzen. Ein Produkt das sich nicht endlos Verkaufen lässt (oder kennt ihr jemanden der jede Woche nen HIV-Test macht ?) Eine Konkurrenz die sehr stark ist, sei es nun die anderen Firmen mit ihren Tests oder einfach nur die bewährten alten Testverfahren. Eine schlechte Informationspolitik seitens der Firma (hat sich mittlerweile stark verbessert). Der Versuch über 200.000.000 neue Aktien die Firma am Leben zu erhalten. Und zu guter Letzt, keine Übernahmefantasie (sollte wirklich ein Pharmariese Interesse an Caly haben gäbe es diese Firma bei ca. 8Mio. Marktkapitalisierung schon lange nicht mehr.)
Noch fragen Hauser.......
Mit freundlichen Grüßen 2Bombi
So, nun start frei für eure Beschimpfungen.......
Investment Pro & Contra Calypte Biomedical
für Calypte spricht:
Sie haben ein fertiges Produkt, einen auf Urin basierenden HIV-Test der von der FDA zugelassen ist was in der Form (Urintest/FDA-Zulassung) einzigartig ist.
gegen Calypte spricht:
Der HIV-Test ist zwar in der Form (Urintest mit FDA-Zulassung) einzigartig, jedoch ist es nicht die einzigste Möglichkeit HIV zu diagnostizieren. Vor dem Calypte-Urintest gab es auch schon Möglichkeiten eine Infektion mit HIV nachzuweisen. Und diese gibt es immer noch !!! Des weiteren gibt es jede Menge Konkurrenz was das testen auf HIV betrifft. Neben dem Urintest von Calypte stehen nämlich jede Menge Bluttests u.a von Chiron/Bio-One usw. zur Auswahl.
So frag ich mich also, was hat also Calypte was andere nicht haben ????
FDA Zulassung des Urintests. Was ist die Wert ?? In China/Afrika/Asien/Süd und Mittelamerika (den „Epizentren“ von HIV ) im Grunde genommen gar nichts da der Einsatz des Tests dort nicht von der FDA-Zulassung abhängig ist. Die Zulassung der FDA ist „nur“ für die USA von übergeordneter Bedeutung andere Länder haben entweder keine (weiß nicht ob es in „3.Welt Ländern“ solche Zulassungsverfahren überhaupt gibt ! ) oder ihre eigenen Stellen wo das Produkt (Medikament) für einen Verkauf genehmigt werden muss. Ob nun eine FDA-Zulassung z.B für Europa unter umständen hilfreich ist lass ich mal ganz außer acht.
Wir haben ein Produkt (das nicht schlecht ist !!!) das verkauft werden muss um Gewinne zu erzielen, wem verkaufen wir es ?? Dem der es braucht, und wer ist das ?? Asien (China) Afrika, Südamerika..... OK, nehmen wir mal an das der Calypte Test 10€ kostet (weiß den genauen Preis im Augenblick nicht), gehen in eben diese Länder und versuchen ihn zu verkaufen. Spätestens hier sollte jedem klar werden das dies nicht so einfach ist! Und zwar aus dem einfachen Grund das 10€ teilweise in diesen Ländern ein ganzer Monatslohn bedeutet. In diesen Ländern wo der Test wohl am nötigsten gebraucht wird, geht es ums nackte überleben und da geht man nicht mal schnell in die Apotheke und holt sich ein HIV-Test. Fazit: Dort wo der größte Umsatz gemacht werden könnte fehlt das Geld, oder wer soll die Tests bezahlen ?? Die WHO ?? Die WHO war aus meiner sicht immer ein Hoffnungsschimmer was einen flächendeckenden Einsatz in solchen Gebieten Betrifft jedoch ist auch sie immer chronisch Pleite und auf fremde Gelder angewiesen. Und selbst wenn sie die Mittel haben bzw. bekommen sollten wer sagt dann das sie den Calypte –Test für dieses vorhaben wählen würden ??? So stelle ich also fest das in den „Wachstumsmärkten“ für Caly nicht all zu viel Wachstum zu generieren ist. Bleibt der Europäische und der US-Markt. Ich schaue mir dabei hier in Deutschland mal die Praxis an, wie wird hier getestet? Anhand von Blutproben wird das Blut in Labors auf HIV Erreger untersucht. Wann ? Bei normal sterblichen bei begründetem Verdacht oder wenn man z.B Blut spendet. Liegt hier eine mögliche Verwendung ??? Ich glaube nicht, da das Blut nicht explizit auf HIV untersucht wird sondern auf mehrere Faktoren. Es muss also so oder so in die Labors warum dann vorher noch mit einem Urintest auf HIV testen ?? Das gleiche gilt für Knochenmarkspender, da wird das Blut auch so nebenbei auf HIV untersucht. Bleiben also „nur“ noch die HIV – Fälle wo einzig und alleine nach einer HIV Infektion gesucht wird da es für viele andere Erkrankungen eh von Nöten ist Blut abzuzapfen. Wer käme da außer die Mädels vom Strich (ist zwar auch ein Wachstumsmarkt aber sicher nicht für Caly) noch in Frage ??? Versicherungen ???
Dieses Einsatzgebiet hab ich oft gehört und wusste nie ob ich darüber lachen soll oder ob es mich schockieren sollte. Der Versicherungsvertreter der mir sagt ich muss einen HIV Test machen bevor er mich versichert den werfe ich gleich wieder raus !!! Und ich glaube auch nicht das so etwas jemals auf einer gesetzlichen Grundlage geschehen würde, oder wird !!!
So schrumpft der Markt für Calypte immer mehr zusammen und wenn wir nun mal annehmen der Calyppte Test währe so einfach wie ein Schwangerschaftstest (was er meines Wissens nicht ist) was bleibt dann noch ???? Immer noch genug Menschen, aber warum sollten die den Calypte Test wählen ???
Nach all diesen Dingen blieb für mich eine Firma die ständig ums Überleben kämpft und schon das ein oder andere mal fast Pleite war. Eine Aktie mit sehr sehr dünnen Umsätzen. Ein Produkt das sich nicht endlos Verkaufen lässt (oder kennt ihr jemanden der jede Woche nen HIV-Test macht ?) Eine Konkurrenz die sehr stark ist, sei es nun die anderen Firmen mit ihren Tests oder einfach nur die bewährten alten Testverfahren. Eine schlechte Informationspolitik seitens der Firma (hat sich mittlerweile stark verbessert). Der Versuch über 200.000.000 neue Aktien die Firma am Leben zu erhalten. Und zu guter Letzt, keine Übernahmefantasie (sollte wirklich ein Pharmariese Interesse an Caly haben gäbe es diese Firma bei ca. 8Mio. Marktkapitalisierung schon lange nicht mehr.)
Noch fragen Hauser.......
Mit freundlichen Grüßen 2Bombi
So, nun start frei für eure Beschimpfungen.......
@2bombi
Nur einige weitere Anregungen.
- Lebensversicherungen in den USA verlangen Test
- Vertriebsstruktur durch meditech international
- Bluttest teurer
- Urintest angenehmer
- Vertrieb in den Entwicklungsländern sicher nicht
in der Apotheke - eher Abgabe über Organisationen
- und denk an all die vielen Bordsteinschwalben
usw. usw.
Gruß Boersenkraehe
Nur einige weitere Anregungen.
- Lebensversicherungen in den USA verlangen Test
- Vertriebsstruktur durch meditech international
- Bluttest teurer
- Urintest angenehmer
- Vertrieb in den Entwicklungsländern sicher nicht
in der Apotheke - eher Abgabe über Organisationen
- und denk an all die vielen Bordsteinschwalben
usw. usw.
Gruß Boersenkraehe
@Börsenkraehe, welch moderate Töne.....
Nur einige weitere Anregungen........die ich gerne kommentiere, wenn es dir recht ist......
------------------------------------------------------------------------------------------------------------------------
- Lebensversicherungen in den USA verlangen Test
Wenn das so ist (hab diesbezüglich noch nix gelesen) verlangen die den Nachweis das du nicht HIV-Positiv bist und nicht das du den Calypte-Urintest machen musst!
------------------------------------------------------------------------------------------------------------------------
- Vertriebsstruktur durch meditech international
ohne würde es ja wohl gar nicht gehen, ist für mich kein Kaufgrund.
------------------------------------------------------------
------------------------------------------------------------
- Bluttest teurer
Was kostet der Calypte Test ??? Bitte um Antwort.
------------------------------------------------------------------------------------------------------------------------
- Urintest angenehmer
Geschmacksache, ich hab keine Angst vor ner Spritze, eher davor mir auf die Hände zu pinkeln... ;-)
------------------------------------------------------------------------------------------------------------------------
- Vertrieb in den Entwicklungsländern sicher nicht
in der Apotheke - eher Abgabe über Organisationen
Wer bestimmt welcher Test eingesetzt wird falls die Finanziellen Mittel vorhanden sind ??? oder anders gefragt glaubt ihr nicht das bei solchen Organisationen eine Chiron bessere Karten hat.....(auch in bezug auf Schmiergeldzahlungen die ich keinem unterstellen will...)
------------------------------------------------------------------------------------------------------------------------
- und denk an all die vielen Bordsteinschwalben
die frag ich heute Abend mit was sie testen.... ;-)
-----------------------------------------------------------------------------------------------------------------------
MfG 2Bombi
Nur einige weitere Anregungen........die ich gerne kommentiere, wenn es dir recht ist......
------------------------------------------------------------------------------------------------------------------------
- Lebensversicherungen in den USA verlangen Test
Wenn das so ist (hab diesbezüglich noch nix gelesen) verlangen die den Nachweis das du nicht HIV-Positiv bist und nicht das du den Calypte-Urintest machen musst!
------------------------------------------------------------------------------------------------------------------------
- Vertriebsstruktur durch meditech international
ohne würde es ja wohl gar nicht gehen, ist für mich kein Kaufgrund.
------------------------------------------------------------
------------------------------------------------------------
- Bluttest teurer
Was kostet der Calypte Test ??? Bitte um Antwort.
------------------------------------------------------------------------------------------------------------------------
- Urintest angenehmer
Geschmacksache, ich hab keine Angst vor ner Spritze, eher davor mir auf die Hände zu pinkeln... ;-)
------------------------------------------------------------------------------------------------------------------------
- Vertrieb in den Entwicklungsländern sicher nicht
in der Apotheke - eher Abgabe über Organisationen
Wer bestimmt welcher Test eingesetzt wird falls die Finanziellen Mittel vorhanden sind ??? oder anders gefragt glaubt ihr nicht das bei solchen Organisationen eine Chiron bessere Karten hat.....(auch in bezug auf Schmiergeldzahlungen die ich keinem unterstellen will...)
------------------------------------------------------------------------------------------------------------------------
- und denk an all die vielen Bordsteinschwalben
die frag ich heute Abend mit was sie testen.... ;-)
-----------------------------------------------------------------------------------------------------------------------
MfG 2Bombi
Test kostet 15 $.
und auch alles weitere ist auch schon publiziert worden. Informiere Dich ordentlich, bevor hier mit Informationslücken diskutiert wird. Schwalbe ROSA hat shcon 100 zu 0,22 gekauft! Letzte Woche waren andere Umsätze, da warst wohl im Urlaub?- Zuvor den Umsatz kritisiert.
Irgentwie versteh ich die Argumentation nicht.
BK
und auch alles weitere ist auch schon publiziert worden. Informiere Dich ordentlich, bevor hier mit Informationslücken diskutiert wird. Schwalbe ROSA hat shcon 100 zu 0,22 gekauft! Letzte Woche waren andere Umsätze, da warst wohl im Urlaub?- Zuvor den Umsatz kritisiert.
Irgentwie versteh ich die Argumentation nicht.
BK
These
Wir schließen in den USA bei 0,24 $, bei geringen Umsatz.
- Bedeutet das, dass Caly bei geringen Volumen
uninteressant ist und der Kurs getürkt ist?
- oder das man sich von 100er oder 400er nicht zum Verkauf
verleiten läßt, weil die Unternehmensnachrichten der
vergangen Monate posetiv waren und man sich mehr
verspricht?
????
Gruß Boersenkraehe
Wir schließen in den USA bei 0,24 $, bei geringen Umsatz.
- Bedeutet das, dass Caly bei geringen Volumen
uninteressant ist und der Kurs getürkt ist?
- oder das man sich von 100er oder 400er nicht zum Verkauf
verleiten läßt, weil die Unternehmensnachrichten der
vergangen Monate posetiv waren und man sich mehr
verspricht?
????
Gruß Boersenkraehe
Aha
Sind ja anscheinend ein paar Mios an Teilen mehr geworden!
Shares Outstanding: 43,540,000
Market Cap: 10.0 Million
Gruß Boersenkraehe
Sind ja anscheinend ein paar Mios an Teilen mehr geworden!
Shares Outstanding: 43,540,000
Market Cap: 10.0 Million
Gruß Boersenkraehe
@Börsenkrähe
Pro & contra Investment Caly .....
je geringer der Umsatz desto schwieriger wird es Aktien zu einem Fairen Preis zu kaufen bzw. zu verkaufen !!!!
Ich habe nach dem Preis des Tests gefragt (wußte ihn nicht !!!) da du gesagt hast das Bluttests teuer sind und um das zu behaupten muss ich die Kosten beider Tests vergleichen.
Also Calypte Urintest = 15 $
Bluttest = ?? $
ich hab nix von getürkten Kursen gesagt, zum Umsatz siehe oben.
Wenn dein Broker keine Transaktionsgebühren verlangt kannst du auch nur eine kaufen.....ansonsten rechne mal nach bis wo der Kurs steigen muss um Gewinne zu machen.
wenn du mit #12 auf die Anzahl an Aktien anspielst, je mehr Aktien Caly auf den Markt wirft desto weniger sind sie Wert!!!
cu 2bombi
Pro & contra Investment Caly .....
je geringer der Umsatz desto schwieriger wird es Aktien zu einem Fairen Preis zu kaufen bzw. zu verkaufen !!!!
Ich habe nach dem Preis des Tests gefragt (wußte ihn nicht !!!) da du gesagt hast das Bluttests teuer sind und um das zu behaupten muss ich die Kosten beider Tests vergleichen.
Also Calypte Urintest = 15 $
Bluttest = ?? $
ich hab nix von getürkten Kursen gesagt, zum Umsatz siehe oben.
Wenn dein Broker keine Transaktionsgebühren verlangt kannst du auch nur eine kaufen.....ansonsten rechne mal nach bis wo der Kurs steigen muss um Gewinne zu machen.
wenn du mit #12 auf die Anzahl an Aktien anspielst, je mehr Aktien Caly auf den Markt wirft desto weniger sind sie Wert!!!
cu 2bombi
@Börsenkrähe
PS: schau dir mal die heutigen Umsätze in FRA an
13.03. Zeit Kursfeststellungen 0 <-- :-(
Aktuell 0,25 B 09:11 Gehandelte Stück 0 <-- :-(
Geld 0,23 18:40 Handelsvolumen -
Brief 0,25 18:40 52W Hoch 1,20
Eröffnung 0,25 52W Tief 0,13
Hoch 0,25 Jahreshoch 0,33
Tief 0,25 Jahrestief 0,17
Schluß Vortag 0,25
PS: schau dir mal die heutigen Umsätze in FRA an
13.03. Zeit Kursfeststellungen 0 <-- :-(
Aktuell 0,25 B 09:11 Gehandelte Stück 0 <-- :-(
Geld 0,23 18:40 Handelsvolumen -
Brief 0,25 18:40 52W Hoch 1,20
Eröffnung 0,25 52W Tief 0,13
Hoch 0,25 Jahreshoch 0,33
Tief 0,25 Jahrestief 0,17
Schluß Vortag 0,25
Wenn Porsche nach guten Ergebnissen und Prognosen eine Kapitalerhöhung durchführt, um die Nachrage befriedigen zu können (Investitionen, sind die Papiere im Anschluß weniger wert. Aha ?????
Ich würd sagen, auf die Stückzahl kommt es wohl nicht allein an. Angebot und Nachfrage machen den Kurs- richtig?
Eine Laboruntersuchung ist natürlich teurer. Bei uns beim Arzt bis 9.00 Uhr abgeben- später gehts nicht - weil es mit dem Kurier/oder besondere Versandform verschickt wird, weil man sonnst nur noch Kristalle in der Röhre hat. Die Kosten, so ist mir in Erinnerung (Krankenkassenbeschäftigung)liegen ausschl. des Arzthonorares bei ca. 80 DM.
Gruß Boersenkraehe
Ich würd sagen, auf die Stückzahl kommt es wohl nicht allein an. Angebot und Nachfrage machen den Kurs- richtig?
Eine Laboruntersuchung ist natürlich teurer. Bei uns beim Arzt bis 9.00 Uhr abgeben- später gehts nicht - weil es mit dem Kurier/oder besondere Versandform verschickt wird, weil man sonnst nur noch Kristalle in der Röhre hat. Die Kosten, so ist mir in Erinnerung (Krankenkassenbeschäftigung)liegen ausschl. des Arzthonorares bei ca. 80 DM.
Gruß Boersenkraehe
Oh meine These trifft wohl zu?
0,24$
Einer der sich sich beruhigt auf die Hände pinkeln kann.
Gruß Börsenkraehe
0,24$
Einer der sich sich beruhigt auf die Hände pinkeln kann.
Gruß Börsenkraehe
Übrigens durch die ca. 3.800.000 neuen Stücke hamse zum durchschnittskurs von 0,18 $ knapp über 650.000 $ in der Kasse.
die 200.000.000 Mio. shares die hier mal im Gespräch waren, waren vermutlich ein Joke von LMB - völliger Unsinn!
Gruß Börsenkraehe
die 200.000.000 Mio. shares die hier mal im Gespräch waren, waren vermutlich ein Joke von LMB - völliger Unsinn!
Gruß Börsenkraehe
Hier zählen nur Fakten !!!
USD 0,24 bei diesem Markt. Der Kurs wird in den USA gemacht.
Bein nächsten Anstieg wird es richtig hochgehen!!!
An solchen Tagen sollte man kaufen ...
USD 0,24 bei diesem Markt. Der Kurs wird in den USA gemacht.
Bein nächsten Anstieg wird es richtig hochgehen!!!
An solchen Tagen sollte man kaufen ...
genau
... deshalb habe ich ja schon rechtzeitig zugeschlagen.
Wie die anscheinend...
ALAMEDA, Calif., Feb 12, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (CALY) announced today that it has signed an agreement to place up to $850,000 in two secured convertible debentures with Bristol Investment Fund, Ltd. ("Bristol"), a private investment fund. The agreement also obligates Bristol to exercise warrants to purchase shares of Calypte`s common stock during the twelve months following the effectiveness of a registration statement that Calypte will file with the Securities and Exchange Commission to register the resale of the shares. Based on current market conditions, if Calypte issues both debentures, Calypte expects that its aggregate net proceeds from the debentures and exercise of the warrants will amount to approximately $2.1 million.
Gruß Boersenkraehe
... deshalb habe ich ja schon rechtzeitig zugeschlagen.
Wie die anscheinend...
ALAMEDA, Calif., Feb 12, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (CALY) announced today that it has signed an agreement to place up to $850,000 in two secured convertible debentures with Bristol Investment Fund, Ltd. ("Bristol"), a private investment fund. The agreement also obligates Bristol to exercise warrants to purchase shares of Calypte`s common stock during the twelve months following the effectiveness of a registration statement that Calypte will file with the Securities and Exchange Commission to register the resale of the shares. Based on current market conditions, if Calypte issues both debentures, Calypte expects that its aggregate net proceeds from the debentures and exercise of the warrants will amount to approximately $2.1 million.
Gruß Boersenkraehe
Hier noch einer...
It’s Over?
Current price: (2/19/02) $0.19
Est. Inst. Ownership: 1.2 million shs.
52-week price range: $0.09 - $1.3125
Est. Insider Ownership: 4.5 million shs.
Outstg. Com. Shrs: 39.8 million (as of 12/31/01)
Est. Float: 34.1 million shs.
Market Cap: $7.6 million
SELECTED ANNUAL DATA
FY: Dec. 31
2001
2002E
2003E
Revenues (000)
$6,826
$10,000
$25,000
Net Income
($9,248)
($5,500)
$3,000
EPS
($0.30)
($0.10)
$0.04
Investment Rationale: With AIDS poised to become the greatest pandemic in world history, surpassing the black plague of medieval times in the number of deaths it will cause, the mission of Calypte Biomedical Corporation, (hereinafter "CALY"), a public healthcare company dedicated to the development of urine-based diagnostic products and services, takes on a role of increasing world importance. Despite the progress that has been made in recent years in finding new drug combinations that suppress the AIDS virus, there is still no vaccine or cure in sight. Accordingly, Calypte testing products create more opportunities for better healthcare by making accurate, comprehensive testing solutions easier, faster, and more accessible. The company’s urine based HIV screening tests make it as simple as possible for people to get the results they need--results that translate into knowledge and the potential for better care. To help stop the spread of AIDS, Calypte Biomedical Corporation is devoted to developing tests that make testing for HIV exposure as easy as possible. Around the world, people need tests for HIV exposure that are simple, quick, inexpensive, and reliable. In our opinion, CALY urine based HIV tests meet these urgent needs. In the years immediately ahead, we believe that there will be greater market acceptance of the company’s products that will lead to strong revenue growth and an emerging trend toward profitability. We view the current price of the CALY shares as not reflecting the growth prospects of the company. Accordingly, for those investors who can tolerate a very high degree of risk, we view the CALY shares as an attractive opportunity, and we are initiating coverage with a STRONG BUY rating.
COMPANY BACKGROUND
Calypte Biomedical Corporation was incorporated in 1989 to pursue the development of urine-based diagnostic tests. Since then, the company has become the leader in urine-based screening tests for the detection of HIV-1, the cause of AIDS. CALY has integrated several proprietary technologies to develop an FDA-approved test, which in clinical trials detected the presence of HIV antibodies in urine with 99.7% sensitivity (as compared with blood tests). Specificity of the screening test with a companion Western Blot confirmatory test was 100%. CALY’s proprietary urine-based test offers significant advantages compared to existing blood–based tests, including ease of use, lower costs, and significantly reduced risk of infection from collecting and handling specimens. Urine collection is non-invasive and painless, and urine is the most commonly collected and tested bodily fluid.
The company went public in July, 1996, with an offering of 2.4 million shares of common stock priced at $6. The company’s headquarters are located at 1265 Harbor Bay Parkway, Alameda, California, 94502. Telephone: 510-749-5100.
KEY CONSIDERATIONS
AIDS continues to be one of the most potent and deadly diseases in world history. Still, progress has been made in many industrial countries in containing the disease, making an early diagnosis of infection all the more important.
Calypte Biomedical is the leader in urine-based screening tests for the detection of HIV-1, the cause of AIDS. CALY integrated several proprietary technologies to develop its test that was approved by the FDA in August 1996.
The company continues to work aggressively on a "rapid" urine-based HIV test that could open up even more opportunities for market penetration.
CALY has forged important strategic relationships. For instance, in early January the company announced that Unilab – the largest testing laboratory in California – would be distributing its products. Moreover, Calypte management is pursuing relationships with other large labs nationwide.
The World Health Organization (WHO) is currently performing tests on the company’s urine- based tests. Any endorsement by the WHO of the urine-based HIV test would be extremely significant. Once the WHO recommends a product, many third world countries could use it, suggesting a huge market potential for CALY.
Another huge potential market for the company is China, where the central government has already approved distribution agreements. Calypte sent its second shipment to China last month.
The company’s management team is comprised of individuals who have substantial scientific and diagnostic experience. Moreover, CALY has assembled an impressive scientific advisory board.
In an effort to improve margins management is aggressively looking at ways to better contain costs, improve margins, and grow the company exponentially.
For the year ended December 31, 2001, CALY reported record revenues of $6,826,000 or 107% greater than the $3,296,000 in the year earlier period.
In the year ending December 31, 2002 we believe that the company’s revenues could more than double, and that by early 2003 a trend toward profitability will have been established.
SIGNIFICANT RECENT DEVELOPMENTS
On January 30, Calypte announced that Unilab Corporation has successfully completed the California licensing requirements to begin offering Calypte`s non-invasive HIV-1 urine antibody tests to clients. Unilab is California`s largest provider of clinical laboratory services, and operates more than 50 laboratories with primary testing facilities in Los Angeles, San Jose and Sacramento, and more than 400 regional service facilities located throughout the state. Unilab will market Calypte`s urine HIV-1 antibody test to all clients as an alternative screening test for HIV. Testing will initially be performed at Unilab`s reference laboratory in Los Angeles.
Late last year, Calypte completed its first urine HIV-1 antibody test shipment of significant size to its distributor in the People`s Republic of China, followed by another shipment in January. These tests are destined for epidemiological uses in at least 15 of the country`s 28 provinces. China has recently announced the creation of a Five-Year Plan against HIV/AIDS. This Plan includes epidemiological baseline screening combined with ongoing surveillance. The company expects its products to play a key role in this effort as the Plan is implemented.
During the third quarter of 2001, the company completed its first shipment of urine HIV-1 EIA tests to its distributor in Malaysia. That distributor is optimistic that additional regulatory reviews currently in process will expand the market for the company`s tests to additional public and private sector entities in Malaysia. The regulatory approval process is moving forward in both the Philippines and South Korea, where, in both cases, the company expects to receive a formal request for a small clinical evaluation in the near future. CALY is also working with its distributor in Brazil to formulate the protocol for a local clinical trial that has been requested by regulatory authorities in that country.
An Alternative to Blood Testing
Traditionally, testing for HIV infection has been done with a serum (blood) test. Calypte urine-based testing creates more opportunities for better healthcare by making accurate, comprehensive testing solutions easier, faster, and more accessible. A positive result means you have HIV antibodies in your body—that you are "HIV positive." Prompt medical care may delay the onset of AIDS, prevent some life-threatening conditions, and help prevent the spread of AIDS. Within 10 years after infection, about half of untreated people have developed AIDS.
CALY’s tests make it as simple as possible for people to get the results they need--results that translate into knowledge and the potential for better care. Around the world, people need tests for HIV exposure that are simple, quick, inexpensive, and reliable. Calypte tests meet those urgent needs. With the exception of blood donor testing, the two components of the urine-based testing algorithm are licensed for use by laboratories in the U.S. and produce very dependable results. Urine testing is a convenient and dependable way to test for HIV infection that can also offer some safety advantages.
Why Test with Urine Instead of Blood?
There are many reasons why individuals might prefer a urine test, including convenience, peace of mind, and safety. In the U.S., studies indicate that nearly 50% of 1,000 people who were asked about a test for HIV said they would prefer a urine test instead of a blood test. Nearly 80% of these people said that it`s because they have a fear of needles. In fact, "needle phobia" is a recently defined medical condition that is estimated to affect at least 10% of people in the U.S. And with a urine test, there is no risk of your healthcare provider being accidentally stuck by a needle as there is with a blood test. There is also no risk that a healthcare worker will accidentally use a needle on you that was used previously on a different patient. There is no infectious HIV in urine, so urine testing is safer for everybody.
The company has integrated several proprietary technologies to develop a test, which, in clinical trials, detected the presence of HIV antibodies in urine with 99.7% sensitivity in subjects known to be HIV-1 infected, as identified through blood-based (serum/plasma) screening tests. In subjects at low risk for HIV (low-risk subjects), the specificity of the screening test with a companion Western Blot supplemental test was 100%. Specificity and sensitivity in other populations, including those at high risk and those with other medical conditions, is reduced compared with testing with blood specimens. The company estimates that the cost of collecting, handling, testing and disposing of urine specimens will be significantly less than that of blood specimens. In August 1996, CALY received a product license and an establishment license from the Food And Drug Administration (FDA) to manufacture and sell, in interstate and foreign commerce, the urine-based HIV-1 screening test for use in professional laboratory settings.
Calypte`s proprietary urine-based HIV-1 screening test is designed to be non-invasive, easy to use and reliable, and avoids many of the costs and risks associated with blood-based testing. This screening test, when used with the Western Blot supplemental test for urine, provides the only complete urine-based HIV testing method. Laboratories using the company`s method can complete the entire testing profile for HIV-1 antibody using a single urine specimen. Moreover, urine tests already are available for determining risk factors for HIV-related transmittal conditions, such as pregnancy, drugs of abuse, and sexually transmitted diseases such as chlamydia and gonorrhea. CALY itself intends to develop additional or improved urine- and blood-based tests for other infectious and viral diseases. The company will also continue to explore the potential for an over-the-counter, in-home urine collection kit.
Technical Analysis of CALY Tests
The Cambridge Biotech HIV-1 Western Blot is an in-vitro qualitative assay for the detection and identification of antibodies to HIV-1. This more specific assay is used as a supplemental test with specimens (serum, plasma or urine) that tested repeatedly reactive using the screening procedure (EIA). The Cambridge Biotech HIV-1 Western Blot is manufactured from HIV-1 propagated in an H9/HTLV-IIIB T-Lymphocyte cell line. The virus is inactivated and specific HIV-1 proteins are bound to a nitrocellulose strip. Each strip contains all of the proteins and glycoproteins of HIV arranged in bands across the strip in order of molecular weight. If HIV-1 antibodies are present in the specimen, they will bind to the viral antigens present on the nitrocellulose strip. The position of bands on the nitrocellulose strips allows this antibody reactivity to be associated with specific viral antigens.
The Company`s urine-based screening test uses an industry-standard 96 well micro titer plate to detect antibodies to HIV-1 in urine. The HIV-1 antibodies, when present in urine, bind to Calypte`s proprietary antigen coated on prepared micro titer plates. A subsequent enzymatic reaction produces a color change revealing the presence of HIV-1 antibodies. The screening test requires only 200 micro liters of urine (approximately four drops), and can be performed using standard laboratory equipment. Samples can be shipped and stored at 15 to 30 degrees centigrade for up to 55 days, or for up to one year at two to eight degrees centigrade, before testing. The laboratory protocol for testing urine is nearly identical to that of blood, and, therefore, requires few, if any, modifications to existing laboratory protocols.
Cambridge Biotech Blood-Based HIV-1 Supplemental Test
The Cambridge Biotech HIV-1 Western Blot kit has been in commercial distribution for more than nine years. Since the FDA`s November, 1999, approval of a Day Assay format, the supplemental test is available in both a five-hour and an overnight format.
Sentinel Testing Service
In May, 2000, CALY launched its participation in a new national urine-based testing service for HIV-1 antibody, chlamydia and gonorrhea. The service is designed to be a painless, non-invasive, urine-based sampling method designed to identify HIV-1 antibody, chlamydia and gonorrhea sexually transmitted diseases (STDs). The Sentinel service provides a three-day response and is priced below the Medicaid reimbursement level in most states. The service is targeted to medical clinics, physicians and community-based organizations. CALY manufactures the HIV-1 antibody tests used in the Sentinel service.
Competing suppliers of blood-based HIV tests in the United States include Abbott Laboratories, Ortho Clinical Diagnostics and Bio-Rad Laboratories. The OraSure collection device, an HIV-screening test designed to use oral fluid, manufactured by OraSure, Inc., used in conjunction with an HIV-1 EIA, received FDA approval for marketing in the United States in December 1994.
AIDS – The World’s Greatest Killer
According to the Family Health International AIDS Institute, a non-governmental agency based in Arlington, Virginia, AIDS will surpass the Black Death as the world`s worst pandemic if the 40 million people living with HIV/AIDS do not get life-prolonging drugs. The illness has killed 25 million people since the early 1980s and an estimated 14,000 people worldwide are infected each day with HIV. Without antiretroviral drugs most people living with HIV/AIDS will die, pushing the death toll beyond the 40 million killed by the Black Death that ravaged Asia and Europe in the 14th century.
Ninety-five percent of new infections are in the world`s poorest countries where life-prolonging drugs are not available to most sufferers.
The illness has decreased life expectancy, increased infant mortality, and orphaned millions of children -- particularly in Sub-Saharan Africa, home to more than 28 million HIV/AIDS sufferers.
The Insurance Industry Market
For the year ended December 31, 2001, Calypte Biomedical announced that its sales to life insurance industry reference laboratories had grown more than 40% compared with the same period last year. The company believes that the benefits of urine testing versus blood testing for insurance applicants include predictive and protective value for insurance companies at significant cost savings. This, combined with the nationwide successful conversion from blood testing to urine testing for a variety of applicants representing different age groups and different policy values has demonstrated to many larger insurance companies that urine is an optimal alternative to blood for testing. The company believes that there will continue to be strong growth in test sales to the insurance industry for several reasons. For instance, urine is an easier and less costly specimen to collect. Moreover, because so many screening tests can be done with one urine specimen, the information available from urine testing provides insurance underwriters with valuable information in assessing the status of an insurance applicant on a very cost-effective basis. CALY’s urine HIV-1 antibody test is only one of the many tests routinely done when urine is tested on an insurance applicant, but it is invaluable in that an HIV test is almost always requested on an applicant.
Indeed, Calypte`s sales efforts with its urine HIV-1 antibody test have convinced 9 of the 10 most admired and prestigious insurance companies (as ranked by Fortune) to adopt urine testing for selected policies. Among these are New York Life, American General, John Hancock, Metropolitan Life, and Prudential. Among those companies that have adopted urine testing for some applicant groups in 2001 are TIAA-CREF, American General, New York Life, Southern Farm Bureau, ING Group, Allmerica Financial, and Berkshire Life.
MANAGEMENT
As is the case with any company, but particularly for companies like CALY, the quality of management is a key element in determining success or failure of the business plan. In the case of Calypte we believe that the company not only has a top-notch executive staff, led by Ms. Nancy Katz, but also is fortunate to have an extremely prestigious Board of Directors, that serves to provide management with very valuable technical input. A brief overview of their collective strengths is offered below.
David E. Collins was elected as the company’s Chairman of the Board in June, 2000. He served as CALY’s Vice Chairman of the Board of Directors from December, 1997, until June, 2000, and has been a member of the Board of Directors since December, 1995. From October, 1999, until June, 2000, he also served as the company`s Chief Executive Officer. From September, 1989, until September, 1994, he served as Executive Vice President with Schering-Plough Corporation, responsible for all over-the-counter and consumer health care products. From February, 1988, to August, 1989, he was a founding partner of Galen Partners, a venture capital firm. From July, 1962, to February 1988, he held several positions at Johnson & Johnson, including Vice Chairman of the Board of Directors for Public Affairs & Planning and Vice Chairman for the Executive Committee & Chairman of the Consumer Sector. Mr. Collins is also a member of the Board of Directors of Ista Pharmaceutical, Inc., a public company, and Lander, Inc., Advanced Corneal Systems, Inc., Beansprout Networks, Inc., and Claneil Enterprises, Inc., all private companies. Mr. Collins received his L.L.B. at Harvard Law School, and his B.A. at the University of Notre Dame.
Nancy Katz is CALY’S President, Chief Executive Officer, and Director. Ms. Katz was elected the company`s President, Chief Executive Officer and Chief Financial Officer in June, 2000. From October, 1999, until June, 2000, she was President, Chief Operating Officer and Chief Financial Officer. She has also been a member of the Board since October, 1999. Prior to joining Calypte, Ms. Katz served as president of Zila Pharm Inc., a prescription and non-prescription oral health care products company. From 1995 to 1998, Ms. Katz led sales and marketing efforts for LifeScan, the diabetes testing division of Johnson & Johnson. Ms. Katz also served as vice president of U.S. marketing, directing LifeScan`s marketing and customer call center departments. During her seven-year career at Schering-Plough Healthcare Products, from 1987 to 1994, she held numerous positions including senior director and general manager, marketing director, Footcare New Products, and product director, OTC New Products. Ms. Katz also held various product management positions at Whitehall Laboratories, a division of American Home Products, from 1981 to 1987. Ms. Katz is a member of the Board of Directors of Neoprobe Corporation. She received her B.A. from the University of South Florida.
Richard Brounstein is CALY’s Chief Financial Officer, Executive Vice President, and Director. Mr. Brounstein`s 29-year career includes a series of senior management positions of increasing responsibility in finance and operations. He has extensive public company exposure, most recently as CFO of Certicom Corp. (NASDAQ: CERT), as well as 12 years of CFO experience with medical technology companies, including VidaMed, Inc. (NASDAQ: VIDA). He has also held positions at Advanced Micro Devices and Arthur Andersen & Co. Brounstein has had responsibility for the accounting, controller, corporate development, information systems, investor relations, human resources, strategic planning, tax and treasury functions, as well as for such operational areas as quality, FDA compliance and facilities management.
John J. DiPietro is a company Director. He is also Vice President of Finance and Administration and CFO of Tripath Technology, Inc. (NASDAQ: TRPH) since 1999. He served as CALY’s Chief Operating Officer, Vice President of Finance, Chief Financial Officer and Secretary from December, 1997, until September, 1999. From October, 1995, until December, 1997, he served as the Vice President of Finance, Chief Financial Officer and Secretary. Prior to joining the Company, he was Vice President of Finance, Chief Financial Officer and Secretary of Meris Laboratories, Inc., a full service clinical laboratory, from 1991 until 1995. He is a Certified Public Accountant and received his M.B.A. from the University of Chicago, Graduate School of Business, and a B.S. in Accounting from Lehigh University. Mr. DiPietro was named a member of the Board of Directors in September, 1999.
Mr. Paul Freiman is a company Director. He has served as a member of the company`s Board of Directors and consultant since December, 1997. He has served as the President and Chief Executive Officer of Neurobiological Technologies, Inc since May, 1997. In 1994, Mr. Freiman retired from his position as Chairman and Chief Executive Officer of Syntex Corporation, a pharmaceutical company. From 1962 until 1994, he held several other positions at Syntex Corporation, including President and Chief Operating Officer.
Dr. Julius R. Krevans has served on the company`s Board of Directors since March, 1995. Dr. Krevans has been Chancellor Emeritus and Director of International Medical Care at University of California at San Francisco since 1993. From 1982 until 1993, Dr. Krevans served as Chancellor at UCSF, and was Dean of the School of Medicine at UCSF from 1971 until 1982. Prior to this, Dr. Krevans served as Dean for Academic Affairs at Johns Hopkins University School of Medicine where he also served on the faculty for 18 years and was Professor of Medicine from 1968 until 1971. Dr. Krevans received his M.D. from New York University, College of Medicine, and completed a residency in Medicine at Johns Hopkins University School of Medicine.Dr. Mark Novitch has served on the company`s Board of Directors since September, 1995. Dr. Novitch was a Professor of Health Care Sciences at George Washington University from October, 1994, to June, 1997. He is presently an Adjunct Professor at George Washington University Medical Center. Since 1993, Dr. Novitch has also been a private consultant in the pharmaceutical industry. From 1985 until 1993, he served in senior executive positions with the Upjohn Company, a medical products company, including Vice Chairman of the Board of Directors, Corporate Executive Vice President, and Corporate Senior Vice President for Scientific Administration and Corporate Vice President. Dr. Novitch received his A.B. from Yale University, and his M.D. from the New York Medical College.
Dr. Zafar Randawa has served on the company`s Board of Directors since December, 1996. Dr. Randawa is currently the Director of the New Technology Evaluation Division of Otsuka America Pharmaceutical, Inc., and has served in this capacity since September, 1995. From 1989 until September, 1995, Dr. Randawa served as a Chief Scientist at Otsuka America Pharmaceutical, Inc.
Claudie E. Williams was elected to the company`s Board of Directors in April, 2000. Ms. Williams is currently Executive Vice President, Mergers and Acquisitions of Claneil Enterprises, Inc., a private holding company. Prior to joining Claneil in January, 2000, Ms. Williams spent 24 years with Johnson & Johnson, Inc., where she worked in both the pharmaceutical and consumer products businesses. From 1975 to 1992, Ms. Williams worked with McNeil Pharmaceutical, a Johnson & Johnson company, where she held a variety of positions in domestic and international marketing and sales. Ms. Williams received her B. A. degree from the University of California at Irvine.
FINANCIAL REVIEW
The company operates on a December 31st Fiscal Year.
For the year ended December 31, 2001, CALY reported record revenues of $6,826,000, or 107% greater than the $3,296,000 achieved in the similar 2000 period. Gross margins for 2001 showed marked improvement approaching breakeven, versus a loss of nearly 80% in 2000. Indeed, for the fourth quarter of last year, the company achieved a first ever-positive gross margin of $579,000, or 25%. The company noted in its news release concerning 2001 results that both revenues and unit sales of all of its continuing products increased in relation to the comparable prior year periods. Revenue from the sale of CALY’s urine HIV screening tests exceeded prior year results by 60% for the full year, and by 78% for the fourth quarter. These big increases in sales of the screening tests reflect strength both domestically and internationally. Full year 2001 sales of the serum Western Blot test more than doubled, and the company reports that demand remains strong in the first quarter of 2002.
During 2001 CALY was successful in reducing its burn rate in every quarter. Additionally, while margins were improving, operating expenses decreased by $1.5 million in 200,1 compared with 2000, with $1 million of the decrease occurring in the fourth quarter. The net loss attributable to common stockholders for the fourth quarter of 2001 was $1.2 million, or $0.03 per share, compared with a net loss attributable to common stock of $3.8 million, or $0.15 per share, for the same quarter of 2000. The net loss for full-year 2001 was $0.30 per share, compared with a net loss of $0.52 per share in 2000.
The company believes that revenue growth prospects for 2002 are strong, and will be fueled by further acceptance of the company’s products both domestically and internationally. We estimate that CALY’s 2002 revenue will be in excess of $10 million, despite near term cash constraints that may result in a slower start for the year. However, if the company is successful in introducing new products during the year 2002, revenues could be higher. While management seems confident that margins will strengthen during 2002, it’s likely that CALY will still post a net loss for the year. However, if 2002 shapes up like we think it can, the stage will have been set for the company to achieve profitability sometime in 2003.
The company’s balance sheet was in relatively weak condition as of December 31, 2001, with cash on hand of just $278,000, and negative working capital of $5 million. However, the company has obtained a new line of credit, obtained some overseas funding, and issued a new convertible debenture that will significantly improve the quality of CALY’s balance sheet and provide the company with new financial flexibility. Still, as a result of this recent financing there could well be nearly double the number of common shares outstanding this time next year. Nevertheless, the benefits of these cash infusions will help the company’s growth prospects significantly, especially in the second half of the year as registration statements still being processed go effective and CALY gains access to these funds. Moreover, in our opinion, its clear that during 2002 management will continue to work on improving the balance sheet and periodic financing can be expected.
RISKS AND CONCERNS
Notwithstanding the tremendous accomplishments of CALY over the past year, a commitment to the shares still encompasses recognizable risk. Generally speaking, the investment environment for small companies remains challenging at best. There is no assurance that even if CALY successfully meets the expectations outlined in this analysis that the company’s stock price can reach our projected target price. Additionally, until the time that CALY can achieve a fully listed status, as it had until July, 2001, as a NASDAQ-listed stock before being assigned to the OTC Bulletin Board, the shares have an added trading risk. Additionally, in order to meet our projections, Calypte must achieve higher sales volumes given the relatively high overhead nature of the business at this time. Investors should also be aware of the substantial dilution, which is discussed above. Finally, we are assuming that a significant amount of future sales growth for the company will be coming from third world countries that usually have a high degree of political risk.
SUMMARY
Our research suggests that CALY is poised to achieve greater market penetration for its urine based HIV tests, and that other products now in the pipeline could prove very successful in promoting the company’s revenue growth. For instance, the prospect of a rapid urine-based HIV test would open many opportunities, as would a test that would encompass the testing for several diseases with one urine sample. Although profitability for CALY is several quarters away, we believe that during 2002 there will be recognition that the company is paring its losses, and that a trend toward profitability is being established. Moreover, if World Health Organization endorsement does, in fact, materialize, CALY will achieve high recognition in the health care industry, which could increase the chances that a large healthcare giant may make a bid for the company. Accordingly, we view the CALY shares as representing an interesting opportunity for high-risk oriented investors to attain well above average capital gains. We have placed a 12-month price target on CALY shares of $2-3.
Barrow Street Research, Inc. (hereafter referred to as BSR) is an independent research firm that produces a comprehensive range of financial oriented publications, including research reports such as the one on Calypte Biomedical Corporation. This report is based on BSR’s independent analysis and judgement but relies on material supplied by the Subject Company and other sources believed to be reliable. The information contained in this report is subject to change without notice, and BSR assumes no responsibility to update information contained in this report. The information contained in this report is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. Investors are advised to consult their personal broker or investment advisor before making any investment decision concerning the Subject Company. In addition, investors are urged to complete their own due diligence on the Subject Company. Investment in Calypte Biomedical, Inc. entails the assumption of a high degree of risk. Access to additional information is available on the BSR web site – www.barrowstreet.com – including links to sites that have additional information on Calypte Biomedical, Inc. BSR has received a fee of $6,000 from a third party – the Investor Relations Network – for the production and distribution of this report.
Game Over - Würd eher sagen, dass hier Sonderspiele anstehen.
Gruß Boersenkraehe
Jeder Steuerberater und jede Unternehmensberatung langt zu. 6000 $ war doch günstig für ein Check.
Gruß Boersenkraehe
#5 von 2Bombi 12.03.02 20:36:24 Beitrag Nr.: 5.778.966 5778966
Dieses Posting: versenden | melden | drucken
@stockhunter02
nimm dir die Zeit und lies dir die Caly-Threads durch
meiner Einschätzung nach gibt es mehr Gründe gegen ein Investment als für ein Investment. Du wirst aber schnell etwas anderes zu hören bekommen ;-)
Schularbeiten wohl selbst nicht gemacht? 2Bombi????
Gruß Boersenkraehe
und morgen ist der 14. März
It’s Over?
Current price: (2/19/02) $0.19
Est. Inst. Ownership: 1.2 million shs.
52-week price range: $0.09 - $1.3125
Est. Insider Ownership: 4.5 million shs.
Outstg. Com. Shrs: 39.8 million (as of 12/31/01)
Est. Float: 34.1 million shs.
Market Cap: $7.6 million
SELECTED ANNUAL DATA
FY: Dec. 31
2001
2002E
2003E
Revenues (000)
$6,826
$10,000
$25,000
Net Income
($9,248)
($5,500)
$3,000
EPS
($0.30)
($0.10)
$0.04
Investment Rationale: With AIDS poised to become the greatest pandemic in world history, surpassing the black plague of medieval times in the number of deaths it will cause, the mission of Calypte Biomedical Corporation, (hereinafter "CALY"), a public healthcare company dedicated to the development of urine-based diagnostic products and services, takes on a role of increasing world importance. Despite the progress that has been made in recent years in finding new drug combinations that suppress the AIDS virus, there is still no vaccine or cure in sight. Accordingly, Calypte testing products create more opportunities for better healthcare by making accurate, comprehensive testing solutions easier, faster, and more accessible. The company’s urine based HIV screening tests make it as simple as possible for people to get the results they need--results that translate into knowledge and the potential for better care. To help stop the spread of AIDS, Calypte Biomedical Corporation is devoted to developing tests that make testing for HIV exposure as easy as possible. Around the world, people need tests for HIV exposure that are simple, quick, inexpensive, and reliable. In our opinion, CALY urine based HIV tests meet these urgent needs. In the years immediately ahead, we believe that there will be greater market acceptance of the company’s products that will lead to strong revenue growth and an emerging trend toward profitability. We view the current price of the CALY shares as not reflecting the growth prospects of the company. Accordingly, for those investors who can tolerate a very high degree of risk, we view the CALY shares as an attractive opportunity, and we are initiating coverage with a STRONG BUY rating.
COMPANY BACKGROUND
Calypte Biomedical Corporation was incorporated in 1989 to pursue the development of urine-based diagnostic tests. Since then, the company has become the leader in urine-based screening tests for the detection of HIV-1, the cause of AIDS. CALY has integrated several proprietary technologies to develop an FDA-approved test, which in clinical trials detected the presence of HIV antibodies in urine with 99.7% sensitivity (as compared with blood tests). Specificity of the screening test with a companion Western Blot confirmatory test was 100%. CALY’s proprietary urine-based test offers significant advantages compared to existing blood–based tests, including ease of use, lower costs, and significantly reduced risk of infection from collecting and handling specimens. Urine collection is non-invasive and painless, and urine is the most commonly collected and tested bodily fluid.
The company went public in July, 1996, with an offering of 2.4 million shares of common stock priced at $6. The company’s headquarters are located at 1265 Harbor Bay Parkway, Alameda, California, 94502. Telephone: 510-749-5100.
KEY CONSIDERATIONS
AIDS continues to be one of the most potent and deadly diseases in world history. Still, progress has been made in many industrial countries in containing the disease, making an early diagnosis of infection all the more important.
Calypte Biomedical is the leader in urine-based screening tests for the detection of HIV-1, the cause of AIDS. CALY integrated several proprietary technologies to develop its test that was approved by the FDA in August 1996.
The company continues to work aggressively on a "rapid" urine-based HIV test that could open up even more opportunities for market penetration.
CALY has forged important strategic relationships. For instance, in early January the company announced that Unilab – the largest testing laboratory in California – would be distributing its products. Moreover, Calypte management is pursuing relationships with other large labs nationwide.
The World Health Organization (WHO) is currently performing tests on the company’s urine- based tests. Any endorsement by the WHO of the urine-based HIV test would be extremely significant. Once the WHO recommends a product, many third world countries could use it, suggesting a huge market potential for CALY.
Another huge potential market for the company is China, where the central government has already approved distribution agreements. Calypte sent its second shipment to China last month.
The company’s management team is comprised of individuals who have substantial scientific and diagnostic experience. Moreover, CALY has assembled an impressive scientific advisory board.
In an effort to improve margins management is aggressively looking at ways to better contain costs, improve margins, and grow the company exponentially.
For the year ended December 31, 2001, CALY reported record revenues of $6,826,000 or 107% greater than the $3,296,000 in the year earlier period.
In the year ending December 31, 2002 we believe that the company’s revenues could more than double, and that by early 2003 a trend toward profitability will have been established.
SIGNIFICANT RECENT DEVELOPMENTS
On January 30, Calypte announced that Unilab Corporation has successfully completed the California licensing requirements to begin offering Calypte`s non-invasive HIV-1 urine antibody tests to clients. Unilab is California`s largest provider of clinical laboratory services, and operates more than 50 laboratories with primary testing facilities in Los Angeles, San Jose and Sacramento, and more than 400 regional service facilities located throughout the state. Unilab will market Calypte`s urine HIV-1 antibody test to all clients as an alternative screening test for HIV. Testing will initially be performed at Unilab`s reference laboratory in Los Angeles.
Late last year, Calypte completed its first urine HIV-1 antibody test shipment of significant size to its distributor in the People`s Republic of China, followed by another shipment in January. These tests are destined for epidemiological uses in at least 15 of the country`s 28 provinces. China has recently announced the creation of a Five-Year Plan against HIV/AIDS. This Plan includes epidemiological baseline screening combined with ongoing surveillance. The company expects its products to play a key role in this effort as the Plan is implemented.
During the third quarter of 2001, the company completed its first shipment of urine HIV-1 EIA tests to its distributor in Malaysia. That distributor is optimistic that additional regulatory reviews currently in process will expand the market for the company`s tests to additional public and private sector entities in Malaysia. The regulatory approval process is moving forward in both the Philippines and South Korea, where, in both cases, the company expects to receive a formal request for a small clinical evaluation in the near future. CALY is also working with its distributor in Brazil to formulate the protocol for a local clinical trial that has been requested by regulatory authorities in that country.
An Alternative to Blood Testing
Traditionally, testing for HIV infection has been done with a serum (blood) test. Calypte urine-based testing creates more opportunities for better healthcare by making accurate, comprehensive testing solutions easier, faster, and more accessible. A positive result means you have HIV antibodies in your body—that you are "HIV positive." Prompt medical care may delay the onset of AIDS, prevent some life-threatening conditions, and help prevent the spread of AIDS. Within 10 years after infection, about half of untreated people have developed AIDS.
CALY’s tests make it as simple as possible for people to get the results they need--results that translate into knowledge and the potential for better care. Around the world, people need tests for HIV exposure that are simple, quick, inexpensive, and reliable. Calypte tests meet those urgent needs. With the exception of blood donor testing, the two components of the urine-based testing algorithm are licensed for use by laboratories in the U.S. and produce very dependable results. Urine testing is a convenient and dependable way to test for HIV infection that can also offer some safety advantages.
Why Test with Urine Instead of Blood?
There are many reasons why individuals might prefer a urine test, including convenience, peace of mind, and safety. In the U.S., studies indicate that nearly 50% of 1,000 people who were asked about a test for HIV said they would prefer a urine test instead of a blood test. Nearly 80% of these people said that it`s because they have a fear of needles. In fact, "needle phobia" is a recently defined medical condition that is estimated to affect at least 10% of people in the U.S. And with a urine test, there is no risk of your healthcare provider being accidentally stuck by a needle as there is with a blood test. There is also no risk that a healthcare worker will accidentally use a needle on you that was used previously on a different patient. There is no infectious HIV in urine, so urine testing is safer for everybody.
The company has integrated several proprietary technologies to develop a test, which, in clinical trials, detected the presence of HIV antibodies in urine with 99.7% sensitivity in subjects known to be HIV-1 infected, as identified through blood-based (serum/plasma) screening tests. In subjects at low risk for HIV (low-risk subjects), the specificity of the screening test with a companion Western Blot supplemental test was 100%. Specificity and sensitivity in other populations, including those at high risk and those with other medical conditions, is reduced compared with testing with blood specimens. The company estimates that the cost of collecting, handling, testing and disposing of urine specimens will be significantly less than that of blood specimens. In August 1996, CALY received a product license and an establishment license from the Food And Drug Administration (FDA) to manufacture and sell, in interstate and foreign commerce, the urine-based HIV-1 screening test for use in professional laboratory settings.
Calypte`s proprietary urine-based HIV-1 screening test is designed to be non-invasive, easy to use and reliable, and avoids many of the costs and risks associated with blood-based testing. This screening test, when used with the Western Blot supplemental test for urine, provides the only complete urine-based HIV testing method. Laboratories using the company`s method can complete the entire testing profile for HIV-1 antibody using a single urine specimen. Moreover, urine tests already are available for determining risk factors for HIV-related transmittal conditions, such as pregnancy, drugs of abuse, and sexually transmitted diseases such as chlamydia and gonorrhea. CALY itself intends to develop additional or improved urine- and blood-based tests for other infectious and viral diseases. The company will also continue to explore the potential for an over-the-counter, in-home urine collection kit.
Technical Analysis of CALY Tests
The Cambridge Biotech HIV-1 Western Blot is an in-vitro qualitative assay for the detection and identification of antibodies to HIV-1. This more specific assay is used as a supplemental test with specimens (serum, plasma or urine) that tested repeatedly reactive using the screening procedure (EIA). The Cambridge Biotech HIV-1 Western Blot is manufactured from HIV-1 propagated in an H9/HTLV-IIIB T-Lymphocyte cell line. The virus is inactivated and specific HIV-1 proteins are bound to a nitrocellulose strip. Each strip contains all of the proteins and glycoproteins of HIV arranged in bands across the strip in order of molecular weight. If HIV-1 antibodies are present in the specimen, they will bind to the viral antigens present on the nitrocellulose strip. The position of bands on the nitrocellulose strips allows this antibody reactivity to be associated with specific viral antigens.
The Company`s urine-based screening test uses an industry-standard 96 well micro titer plate to detect antibodies to HIV-1 in urine. The HIV-1 antibodies, when present in urine, bind to Calypte`s proprietary antigen coated on prepared micro titer plates. A subsequent enzymatic reaction produces a color change revealing the presence of HIV-1 antibodies. The screening test requires only 200 micro liters of urine (approximately four drops), and can be performed using standard laboratory equipment. Samples can be shipped and stored at 15 to 30 degrees centigrade for up to 55 days, or for up to one year at two to eight degrees centigrade, before testing. The laboratory protocol for testing urine is nearly identical to that of blood, and, therefore, requires few, if any, modifications to existing laboratory protocols.
Cambridge Biotech Blood-Based HIV-1 Supplemental Test
The Cambridge Biotech HIV-1 Western Blot kit has been in commercial distribution for more than nine years. Since the FDA`s November, 1999, approval of a Day Assay format, the supplemental test is available in both a five-hour and an overnight format.
Sentinel Testing Service
In May, 2000, CALY launched its participation in a new national urine-based testing service for HIV-1 antibody, chlamydia and gonorrhea. The service is designed to be a painless, non-invasive, urine-based sampling method designed to identify HIV-1 antibody, chlamydia and gonorrhea sexually transmitted diseases (STDs). The Sentinel service provides a three-day response and is priced below the Medicaid reimbursement level in most states. The service is targeted to medical clinics, physicians and community-based organizations. CALY manufactures the HIV-1 antibody tests used in the Sentinel service.
Competing suppliers of blood-based HIV tests in the United States include Abbott Laboratories, Ortho Clinical Diagnostics and Bio-Rad Laboratories. The OraSure collection device, an HIV-screening test designed to use oral fluid, manufactured by OraSure, Inc., used in conjunction with an HIV-1 EIA, received FDA approval for marketing in the United States in December 1994.
AIDS – The World’s Greatest Killer
According to the Family Health International AIDS Institute, a non-governmental agency based in Arlington, Virginia, AIDS will surpass the Black Death as the world`s worst pandemic if the 40 million people living with HIV/AIDS do not get life-prolonging drugs. The illness has killed 25 million people since the early 1980s and an estimated 14,000 people worldwide are infected each day with HIV. Without antiretroviral drugs most people living with HIV/AIDS will die, pushing the death toll beyond the 40 million killed by the Black Death that ravaged Asia and Europe in the 14th century.
Ninety-five percent of new infections are in the world`s poorest countries where life-prolonging drugs are not available to most sufferers.
The illness has decreased life expectancy, increased infant mortality, and orphaned millions of children -- particularly in Sub-Saharan Africa, home to more than 28 million HIV/AIDS sufferers.
The Insurance Industry Market
For the year ended December 31, 2001, Calypte Biomedical announced that its sales to life insurance industry reference laboratories had grown more than 40% compared with the same period last year. The company believes that the benefits of urine testing versus blood testing for insurance applicants include predictive and protective value for insurance companies at significant cost savings. This, combined with the nationwide successful conversion from blood testing to urine testing for a variety of applicants representing different age groups and different policy values has demonstrated to many larger insurance companies that urine is an optimal alternative to blood for testing. The company believes that there will continue to be strong growth in test sales to the insurance industry for several reasons. For instance, urine is an easier and less costly specimen to collect. Moreover, because so many screening tests can be done with one urine specimen, the information available from urine testing provides insurance underwriters with valuable information in assessing the status of an insurance applicant on a very cost-effective basis. CALY’s urine HIV-1 antibody test is only one of the many tests routinely done when urine is tested on an insurance applicant, but it is invaluable in that an HIV test is almost always requested on an applicant.
Indeed, Calypte`s sales efforts with its urine HIV-1 antibody test have convinced 9 of the 10 most admired and prestigious insurance companies (as ranked by Fortune) to adopt urine testing for selected policies. Among these are New York Life, American General, John Hancock, Metropolitan Life, and Prudential. Among those companies that have adopted urine testing for some applicant groups in 2001 are TIAA-CREF, American General, New York Life, Southern Farm Bureau, ING Group, Allmerica Financial, and Berkshire Life.
MANAGEMENT
As is the case with any company, but particularly for companies like CALY, the quality of management is a key element in determining success or failure of the business plan. In the case of Calypte we believe that the company not only has a top-notch executive staff, led by Ms. Nancy Katz, but also is fortunate to have an extremely prestigious Board of Directors, that serves to provide management with very valuable technical input. A brief overview of their collective strengths is offered below.
David E. Collins was elected as the company’s Chairman of the Board in June, 2000. He served as CALY’s Vice Chairman of the Board of Directors from December, 1997, until June, 2000, and has been a member of the Board of Directors since December, 1995. From October, 1999, until June, 2000, he also served as the company`s Chief Executive Officer. From September, 1989, until September, 1994, he served as Executive Vice President with Schering-Plough Corporation, responsible for all over-the-counter and consumer health care products. From February, 1988, to August, 1989, he was a founding partner of Galen Partners, a venture capital firm. From July, 1962, to February 1988, he held several positions at Johnson & Johnson, including Vice Chairman of the Board of Directors for Public Affairs & Planning and Vice Chairman for the Executive Committee & Chairman of the Consumer Sector. Mr. Collins is also a member of the Board of Directors of Ista Pharmaceutical, Inc., a public company, and Lander, Inc., Advanced Corneal Systems, Inc., Beansprout Networks, Inc., and Claneil Enterprises, Inc., all private companies. Mr. Collins received his L.L.B. at Harvard Law School, and his B.A. at the University of Notre Dame.
Nancy Katz is CALY’S President, Chief Executive Officer, and Director. Ms. Katz was elected the company`s President, Chief Executive Officer and Chief Financial Officer in June, 2000. From October, 1999, until June, 2000, she was President, Chief Operating Officer and Chief Financial Officer. She has also been a member of the Board since October, 1999. Prior to joining Calypte, Ms. Katz served as president of Zila Pharm Inc., a prescription and non-prescription oral health care products company. From 1995 to 1998, Ms. Katz led sales and marketing efforts for LifeScan, the diabetes testing division of Johnson & Johnson. Ms. Katz also served as vice president of U.S. marketing, directing LifeScan`s marketing and customer call center departments. During her seven-year career at Schering-Plough Healthcare Products, from 1987 to 1994, she held numerous positions including senior director and general manager, marketing director, Footcare New Products, and product director, OTC New Products. Ms. Katz also held various product management positions at Whitehall Laboratories, a division of American Home Products, from 1981 to 1987. Ms. Katz is a member of the Board of Directors of Neoprobe Corporation. She received her B.A. from the University of South Florida.
Richard Brounstein is CALY’s Chief Financial Officer, Executive Vice President, and Director. Mr. Brounstein`s 29-year career includes a series of senior management positions of increasing responsibility in finance and operations. He has extensive public company exposure, most recently as CFO of Certicom Corp. (NASDAQ: CERT), as well as 12 years of CFO experience with medical technology companies, including VidaMed, Inc. (NASDAQ: VIDA). He has also held positions at Advanced Micro Devices and Arthur Andersen & Co. Brounstein has had responsibility for the accounting, controller, corporate development, information systems, investor relations, human resources, strategic planning, tax and treasury functions, as well as for such operational areas as quality, FDA compliance and facilities management.
John J. DiPietro is a company Director. He is also Vice President of Finance and Administration and CFO of Tripath Technology, Inc. (NASDAQ: TRPH) since 1999. He served as CALY’s Chief Operating Officer, Vice President of Finance, Chief Financial Officer and Secretary from December, 1997, until September, 1999. From October, 1995, until December, 1997, he served as the Vice President of Finance, Chief Financial Officer and Secretary. Prior to joining the Company, he was Vice President of Finance, Chief Financial Officer and Secretary of Meris Laboratories, Inc., a full service clinical laboratory, from 1991 until 1995. He is a Certified Public Accountant and received his M.B.A. from the University of Chicago, Graduate School of Business, and a B.S. in Accounting from Lehigh University. Mr. DiPietro was named a member of the Board of Directors in September, 1999.
Mr. Paul Freiman is a company Director. He has served as a member of the company`s Board of Directors and consultant since December, 1997. He has served as the President and Chief Executive Officer of Neurobiological Technologies, Inc since May, 1997. In 1994, Mr. Freiman retired from his position as Chairman and Chief Executive Officer of Syntex Corporation, a pharmaceutical company. From 1962 until 1994, he held several other positions at Syntex Corporation, including President and Chief Operating Officer.
Dr. Julius R. Krevans has served on the company`s Board of Directors since March, 1995. Dr. Krevans has been Chancellor Emeritus and Director of International Medical Care at University of California at San Francisco since 1993. From 1982 until 1993, Dr. Krevans served as Chancellor at UCSF, and was Dean of the School of Medicine at UCSF from 1971 until 1982. Prior to this, Dr. Krevans served as Dean for Academic Affairs at Johns Hopkins University School of Medicine where he also served on the faculty for 18 years and was Professor of Medicine from 1968 until 1971. Dr. Krevans received his M.D. from New York University, College of Medicine, and completed a residency in Medicine at Johns Hopkins University School of Medicine.Dr. Mark Novitch has served on the company`s Board of Directors since September, 1995. Dr. Novitch was a Professor of Health Care Sciences at George Washington University from October, 1994, to June, 1997. He is presently an Adjunct Professor at George Washington University Medical Center. Since 1993, Dr. Novitch has also been a private consultant in the pharmaceutical industry. From 1985 until 1993, he served in senior executive positions with the Upjohn Company, a medical products company, including Vice Chairman of the Board of Directors, Corporate Executive Vice President, and Corporate Senior Vice President for Scientific Administration and Corporate Vice President. Dr. Novitch received his A.B. from Yale University, and his M.D. from the New York Medical College.
Dr. Zafar Randawa has served on the company`s Board of Directors since December, 1996. Dr. Randawa is currently the Director of the New Technology Evaluation Division of Otsuka America Pharmaceutical, Inc., and has served in this capacity since September, 1995. From 1989 until September, 1995, Dr. Randawa served as a Chief Scientist at Otsuka America Pharmaceutical, Inc.
Claudie E. Williams was elected to the company`s Board of Directors in April, 2000. Ms. Williams is currently Executive Vice President, Mergers and Acquisitions of Claneil Enterprises, Inc., a private holding company. Prior to joining Claneil in January, 2000, Ms. Williams spent 24 years with Johnson & Johnson, Inc., where she worked in both the pharmaceutical and consumer products businesses. From 1975 to 1992, Ms. Williams worked with McNeil Pharmaceutical, a Johnson & Johnson company, where she held a variety of positions in domestic and international marketing and sales. Ms. Williams received her B. A. degree from the University of California at Irvine.
FINANCIAL REVIEW
The company operates on a December 31st Fiscal Year.
For the year ended December 31, 2001, CALY reported record revenues of $6,826,000, or 107% greater than the $3,296,000 achieved in the similar 2000 period. Gross margins for 2001 showed marked improvement approaching breakeven, versus a loss of nearly 80% in 2000. Indeed, for the fourth quarter of last year, the company achieved a first ever-positive gross margin of $579,000, or 25%. The company noted in its news release concerning 2001 results that both revenues and unit sales of all of its continuing products increased in relation to the comparable prior year periods. Revenue from the sale of CALY’s urine HIV screening tests exceeded prior year results by 60% for the full year, and by 78% for the fourth quarter. These big increases in sales of the screening tests reflect strength both domestically and internationally. Full year 2001 sales of the serum Western Blot test more than doubled, and the company reports that demand remains strong in the first quarter of 2002.
During 2001 CALY was successful in reducing its burn rate in every quarter. Additionally, while margins were improving, operating expenses decreased by $1.5 million in 200,1 compared with 2000, with $1 million of the decrease occurring in the fourth quarter. The net loss attributable to common stockholders for the fourth quarter of 2001 was $1.2 million, or $0.03 per share, compared with a net loss attributable to common stock of $3.8 million, or $0.15 per share, for the same quarter of 2000. The net loss for full-year 2001 was $0.30 per share, compared with a net loss of $0.52 per share in 2000.
The company believes that revenue growth prospects for 2002 are strong, and will be fueled by further acceptance of the company’s products both domestically and internationally. We estimate that CALY’s 2002 revenue will be in excess of $10 million, despite near term cash constraints that may result in a slower start for the year. However, if the company is successful in introducing new products during the year 2002, revenues could be higher. While management seems confident that margins will strengthen during 2002, it’s likely that CALY will still post a net loss for the year. However, if 2002 shapes up like we think it can, the stage will have been set for the company to achieve profitability sometime in 2003.
The company’s balance sheet was in relatively weak condition as of December 31, 2001, with cash on hand of just $278,000, and negative working capital of $5 million. However, the company has obtained a new line of credit, obtained some overseas funding, and issued a new convertible debenture that will significantly improve the quality of CALY’s balance sheet and provide the company with new financial flexibility. Still, as a result of this recent financing there could well be nearly double the number of common shares outstanding this time next year. Nevertheless, the benefits of these cash infusions will help the company’s growth prospects significantly, especially in the second half of the year as registration statements still being processed go effective and CALY gains access to these funds. Moreover, in our opinion, its clear that during 2002 management will continue to work on improving the balance sheet and periodic financing can be expected.
RISKS AND CONCERNS
Notwithstanding the tremendous accomplishments of CALY over the past year, a commitment to the shares still encompasses recognizable risk. Generally speaking, the investment environment for small companies remains challenging at best. There is no assurance that even if CALY successfully meets the expectations outlined in this analysis that the company’s stock price can reach our projected target price. Additionally, until the time that CALY can achieve a fully listed status, as it had until July, 2001, as a NASDAQ-listed stock before being assigned to the OTC Bulletin Board, the shares have an added trading risk. Additionally, in order to meet our projections, Calypte must achieve higher sales volumes given the relatively high overhead nature of the business at this time. Investors should also be aware of the substantial dilution, which is discussed above. Finally, we are assuming that a significant amount of future sales growth for the company will be coming from third world countries that usually have a high degree of political risk.
SUMMARY
Our research suggests that CALY is poised to achieve greater market penetration for its urine based HIV tests, and that other products now in the pipeline could prove very successful in promoting the company’s revenue growth. For instance, the prospect of a rapid urine-based HIV test would open many opportunities, as would a test that would encompass the testing for several diseases with one urine sample. Although profitability for CALY is several quarters away, we believe that during 2002 there will be recognition that the company is paring its losses, and that a trend toward profitability is being established. Moreover, if World Health Organization endorsement does, in fact, materialize, CALY will achieve high recognition in the health care industry, which could increase the chances that a large healthcare giant may make a bid for the company. Accordingly, we view the CALY shares as representing an interesting opportunity for high-risk oriented investors to attain well above average capital gains. We have placed a 12-month price target on CALY shares of $2-3.
Barrow Street Research, Inc. (hereafter referred to as BSR) is an independent research firm that produces a comprehensive range of financial oriented publications, including research reports such as the one on Calypte Biomedical Corporation. This report is based on BSR’s independent analysis and judgement but relies on material supplied by the Subject Company and other sources believed to be reliable. The information contained in this report is subject to change without notice, and BSR assumes no responsibility to update information contained in this report. The information contained in this report is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. Investors are advised to consult their personal broker or investment advisor before making any investment decision concerning the Subject Company. In addition, investors are urged to complete their own due diligence on the Subject Company. Investment in Calypte Biomedical, Inc. entails the assumption of a high degree of risk. Access to additional information is available on the BSR web site – www.barrowstreet.com – including links to sites that have additional information on Calypte Biomedical, Inc. BSR has received a fee of $6,000 from a third party – the Investor Relations Network – for the production and distribution of this report.
Game Over - Würd eher sagen, dass hier Sonderspiele anstehen.
Gruß Boersenkraehe
Jeder Steuerberater und jede Unternehmensberatung langt zu. 6000 $ war doch günstig für ein Check.
Gruß Boersenkraehe
#5 von 2Bombi 12.03.02 20:36:24 Beitrag Nr.: 5.778.966 5778966
Dieses Posting: versenden | melden | drucken
@stockhunter02
nimm dir die Zeit und lies dir die Caly-Threads durch
meiner Einschätzung nach gibt es mehr Gründe gegen ein Investment als für ein Investment. Du wirst aber schnell etwas anderes zu hören bekommen ;-)
Schularbeiten wohl selbst nicht gemacht? 2Bombi????
Gruß Boersenkraehe
und morgen ist der 14. März
@2Bombi
Ich hab das alles ausgependelt-ist schon ok.
Ist auch nicht schlimm, wenn du dich erst wieder meldest, wenn der Kurs mit 100 Stk. auf 0,22 $ oder 0,21 § geordert werden sollte.
Gruß Boersenkraehe
Ich hab das alles ausgependelt-ist schon ok.
Ist auch nicht schlimm, wenn du dich erst wieder meldest, wenn der Kurs mit 100 Stk. auf 0,22 $ oder 0,21 § geordert werden sollte.
Gruß Boersenkraehe
Calypte HIV-1 Urine EIA exhibits strong performance in Brazilian Study; Correctly Identifies All Positives With Major HIV-1 Subtypes
WEDNESDAY, MARCH 13, 2002 9:25 PM
- BusinessWire
ALAMEDA, Calif., Mar 13, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that in a recently completed Brazilian study Calypte`s HIV-1 Urine EIA achieved 100% sensitivity, evidence that the urine EIA can detect the major HIV-1 subtypes in Brazil.
A large number of HIV-1 subtypes circulate in different parts of Brazil. Patients in this study were shown to be infected with three major subtypes (B, B" and F). All 76 patients identified as HIV-1 positive by blood testing were also shown to be repeatedly reactive with the Calypte HIV-1 Urine EIA test.
In addition, the urine EIA correctly identified 278 of 284 negative samples for a specificity of 97.9%. According to common practice, the six EIA repeatedly reactive specimens would subsequently be subjected to the urine Western Blot assay for final interpretation of the HIV-1 antibody status.
"Urine is an excellent alternative to blood for HIV antibody detection due to the ease of collection without the need of special devices as in saliva collection and the absence of infectious virus particles," offered Dr. Walter Oelemann, one of the principal investigators in this study. "Our results suggest that the Calypte HIV-1 Urine EIA is a good screening test suitable for developing countries like Brazil. As for all screening tests on the market, it is not specific enough as a one-step test and therefore requires confirmation".
"We are very pleased with the outcome of the study," said Dr. Toby Gottfried, Chief Science Officer at Calypte. "These findings are consistent with clinical and post market studies completed in the United States for our urine test."
Outside of the United States, Brazil has the highest number of HIV cases in the Western hemisphere. Calypte is currently pursuing the registration of its urine HIV-1 assays in Brazil. Health authorities in Brazil are determining the design of clinical studies for the evaluation of the Calypte HIV-1 Urine EIA.
Full results will be published in an article titled "Diagnostic Detection of Human Immunodeficiency Virus Type 1 Antibodies in Urine: a Brazilian Study" in the March volume of the Journal of Clinical Microbiology http://jcm.asm.org/cgi/content/abstract/40/3/881.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Toby D. Gottfried, Ph.D., 510/749-5100
Dick VanMaanen, 909/279-8884
www.calypte.com
URL: http://www.businesswire.com
WEDNESDAY, MARCH 13, 2002 9:25 PM
- BusinessWire
ALAMEDA, Calif., Mar 13, 2002 (BW HealthWire) -- Calypte Biomedical Corporation (OTCBB:CALY), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that in a recently completed Brazilian study Calypte`s HIV-1 Urine EIA achieved 100% sensitivity, evidence that the urine EIA can detect the major HIV-1 subtypes in Brazil.
A large number of HIV-1 subtypes circulate in different parts of Brazil. Patients in this study were shown to be infected with three major subtypes (B, B" and F). All 76 patients identified as HIV-1 positive by blood testing were also shown to be repeatedly reactive with the Calypte HIV-1 Urine EIA test.
In addition, the urine EIA correctly identified 278 of 284 negative samples for a specificity of 97.9%. According to common practice, the six EIA repeatedly reactive specimens would subsequently be subjected to the urine Western Blot assay for final interpretation of the HIV-1 antibody status.
"Urine is an excellent alternative to blood for HIV antibody detection due to the ease of collection without the need of special devices as in saliva collection and the absence of infectious virus particles," offered Dr. Walter Oelemann, one of the principal investigators in this study. "Our results suggest that the Calypte HIV-1 Urine EIA is a good screening test suitable for developing countries like Brazil. As for all screening tests on the market, it is not specific enough as a one-step test and therefore requires confirmation".
"We are very pleased with the outcome of the study," said Dr. Toby Gottfried, Chief Science Officer at Calypte. "These findings are consistent with clinical and post market studies completed in the United States for our urine test."
Outside of the United States, Brazil has the highest number of HIV cases in the Western hemisphere. Calypte is currently pursuing the registration of its urine HIV-1 assays in Brazil. Health authorities in Brazil are determining the design of clinical studies for the evaluation of the Calypte HIV-1 Urine EIA.
Full results will be published in an article titled "Diagnostic Detection of Human Immunodeficiency Virus Type 1 Antibodies in Urine: a Brazilian Study" in the March volume of the Journal of Clinical Microbiology http://jcm.asm.org/cgi/content/abstract/40/3/881.
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management`s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company`s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2001 and its subsequent filings with the SEC.
CONTACT: Calypte Biomedical Corporation
Toby D. Gottfried, Ph.D., 510/749-5100
Dick VanMaanen, 909/279-8884
www.calypte.com
URL: http://www.businesswire.com
Wenn Porsche nach guten Ergebnissen und Prognosen eine Kapitalerhöhung durchführt, um die Nachrage (welche Nachfrage ??? )befriedigen zu können (Investitionen, sind die Papiere im Anschluß weniger wert. Aha ?????
Ja !
Ja !
Noch ist Zeit.
A rebroadcast of the Calypte presentation at The Wall Street Analyst Forum`s Institutional Investor Conference can be accessed from the company`s website at www.calypte.com through March 14, 2002.
Gruß Boersenkraehe
A rebroadcast of the Calypte presentation at The Wall Street Analyst Forum`s Institutional Investor Conference can be accessed from the company`s website at www.calypte.com through March 14, 2002.
Gruß Boersenkraehe
typischer fall von : sell (off) on goode news...
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
12:39:09 PM Trade (at Ask) 0.215 5000 OTC BB
12:09:27 PM Trade (at Ask) 0.215 7000 OTC BB
12:09:25 PM Ask 0.215 5000 OTC BB
11:52:48 AM Trade (at Ask) 0.22 1000 OTC BB
11:45:18 AM Trade (at Ask) 0.22 1000 OTC BB
11:32:09 AM Trade (at Ask) 0.22 5000 OTC BB
11:31:57 AM Trade (at Ask) 0.22 2000 OTC BB
11:31:55 AM Trade (at Ask) 0.22 4000 OTC BB
11:31:25 AM Trade (at Ask) 0.22 3000 OTC BB
11:31:25 AM Trade (at Ask) 0.22 800 OTC BB
11:31:03 AM Trade (at Ask) 0.22 10000 OTC BB
11:30:49 AM Ask 0.22 5000 OTC BB
11:30:40 AM Bid 0.21 5000 OTC BB
11:21:36 AM Trade 0.24 5000 OTC BB
11:21:21 AM Ask 0.23 5000 OTC BB
11:11:17 AM Trade (at Ask) 0.24 300 OTC BB
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
12:39:09 PM Trade (at Ask) 0.215 5000 OTC BB
12:09:27 PM Trade (at Ask) 0.215 7000 OTC BB
12:09:25 PM Ask 0.215 5000 OTC BB
11:52:48 AM Trade (at Ask) 0.22 1000 OTC BB
11:45:18 AM Trade (at Ask) 0.22 1000 OTC BB
11:32:09 AM Trade (at Ask) 0.22 5000 OTC BB
11:31:57 AM Trade (at Ask) 0.22 2000 OTC BB
11:31:55 AM Trade (at Ask) 0.22 4000 OTC BB
11:31:25 AM Trade (at Ask) 0.22 3000 OTC BB
11:31:25 AM Trade (at Ask) 0.22 800 OTC BB
11:31:03 AM Trade (at Ask) 0.22 10000 OTC BB
11:30:49 AM Ask 0.22 5000 OTC BB
11:30:40 AM Bid 0.21 5000 OTC BB
11:21:36 AM Trade 0.24 5000 OTC BB
11:21:21 AM Ask 0.23 5000 OTC BB
11:11:17 AM Trade (at Ask) 0.24 300 OTC BB
@joelu
Es geht zwar runter ,aber als Selloff kann man das nicht bezeichnen.
Das sieht man doch an den Times&Sales.
Gruß Taboa
Es geht zwar runter ,aber als Selloff kann man das nicht bezeichnen.
Das sieht man doch an den Times&Sales.
Gruß Taboa
@joelu
Oder du meinst sowas wie Winterschlussverkauf,danach gibt es alles nur noch teurer.
Gruß Taboa
Oder du meinst sowas wie Winterschlussverkauf,danach gibt es alles nur noch teurer.
Gruß Taboa
Das verstehe ich nicht. Es werden riesen Packete zum Ask gekauft und trotzdem geht der Kurs in die Knie.
Kann jeder sagen was er will, aber ich bin 100% überzeugt, dass der Kurs manipuliert wird.
david
Kann jeder sagen was er will, aber ich bin 100% überzeugt, dass der Kurs manipuliert wird.
david
So und in Kürze haben sie alle Happy Happy gemacht. Dann wollen wir doch mal sehen, ob sie dann klarer denken können. Bei uns - wenn man die Chance hat den Kurs zu machen- fallen hier alle um wie die Fliegen. Bleibt doch mal locker dann läuft das auch (wir müssen die aushebeln). Nach 8 Uhr gehts gen Norden, sagt meine Untermieterin im Dachboden.
Sell off - sehe ich auch nicht.
Gruß Boersenkraehe
Sell off - sehe ich auch nicht.
Gruß Boersenkraehe
oder ist das noch der Restbestand zum Angebot?
Müßte doch fast abgewickelt sein. ca. 3.800.000 Teile sind doch schon gelaufen.
BK
Müßte doch fast abgewickelt sein. ca. 3.800.000 Teile sind doch schon gelaufen.
BK
david1
Das sehe ich auch so ,es wurde fast immer im Ask gekauft und trotzdem nach unten gestellt.
War gestern oder so ,auch schon sehr komisch.
Zackzack purzeln die bids und asks runter ,obwohl vorher nur im Ask gekauft wurde.
An der OTC machen die was sie wollen,wollte schon oft knapp über dem Bid ordern,es sind Stücke unter meinen Bid gelaufen und ich hab keine bekommen.Consors meinte ,die sind dazu nicht verpflichtet.
Was solls.
Gruß Taboa
Das sehe ich auch so ,es wurde fast immer im Ask gekauft und trotzdem nach unten gestellt.
War gestern oder so ,auch schon sehr komisch.
Zackzack purzeln die bids und asks runter ,obwohl vorher nur im Ask gekauft wurde.
An der OTC machen die was sie wollen,wollte schon oft knapp über dem Bid ordern,es sind Stücke unter meinen Bid gelaufen und ich hab keine bekommen.Consors meinte ,die sind dazu nicht verpflichtet.
Was solls.
Gruß Taboa
So wie es aussieht gabs die Rabattmarken auch in Frankfurt. Kaum zu glauben - 0,23 !
Gruß Boersenkraehe
Gruß Boersenkraehe
@Boersenkraehe
Allerdings o,23€ ist ja billiger als drüben,das gibt es selten.Sind bestimmt die ,die heute teuer eingekauft haben ,der Zock hat nicht geklappt ,die Aktie kennt man nicht,schnell weg damit.
Gruß Taboa
Ist schon traurig , der Schlusskurs zeigt jetzt in meinem Depot 0,22€ an.
Allerdings o,23€ ist ja billiger als drüben,das gibt es selten.Sind bestimmt die ,die heute teuer eingekauft haben ,der Zock hat nicht geklappt ,die Aktie kennt man nicht,schnell weg damit.
Gruß Taboa
Ist schon traurig , der Schlusskurs zeigt jetzt in meinem Depot 0,22€ an.
das ist ja zum mäuse melken!!!!!was muss noch passieren das der kurs mal über 0,30€ geht!!waaaaaass!!bIN SCHON LANGE IN CALY INVESTIERT UND BLEIBE ES AUCH:::es nervt nur tierrisch.da versteh mal einer die amis.bei uns alleine wären die längst über 0,50€ an was liegt´s den noch?? an der bekanntheit??
@Intrader78
An OTC-BB Markt wird betrogen, geschoben und manipuliert. Bei uns wird das schon ein Fall für die Staatsanwalschaft.
Warum reagiert die Nancy nicht?
david
An OTC-BB Markt wird betrogen, geschoben und manipuliert. Bei uns wird das schon ein Fall für die Staatsanwalschaft.
Warum reagiert die Nancy nicht?
david
was geht da eigentlich ab
Schaut Euch das an!!!!!!
3:43:55 PM Trade (at Bid) 0.2 50000 OTC BB
3:43:37 PM Trade (at Ask) 0.21 50000 OTC BB
3:40:07 PM Trade (at Bid) 0.2 50000 OTC BB
3:39:59 PM Trade (at Ask) 0.21 10000 OTC BB
3:33:50 PM Trade (at Ask) 0.21 50000 OTC BB
Da stimmt doch was nicht oder????????
3:43:55 PM Trade (at Bid) 0.2 50000 OTC BB
3:43:37 PM Trade (at Ask) 0.21 50000 OTC BB
3:40:07 PM Trade (at Bid) 0.2 50000 OTC BB
3:39:59 PM Trade (at Ask) 0.21 10000 OTC BB
3:33:50 PM Trade (at Ask) 0.21 50000 OTC BB
Da stimmt doch was nicht oder????????
genau das ist völlig hohl und ich beobachte das seit Wochen realtime ,oft genug versucht in solchen Situationen welche zu kaufen,wie gesagt im bid fast unmöglich ,wenn dann im ask.Öfters hatte ich versucht ein neues bid zustellen,daß wurde Stunden nicht gemacht ,irgendwann wurde das bid umgestellt,100000St. gingen 1cent unter den bid ,aber ich hatte wieder keine.Davon gibt es viele verschiedene Geschichten,es ist unglaublich .
Gruß Taboa
Gruß Taboa
Es wird ein Versuch Wert, Nancy eine E-mail zu schreiben.
Die Frau kann doch nicht blind sein, oder?
Es ist offensichtlich, dass hier ein Betrug vorliegt.
david
Die Frau kann doch nicht blind sein, oder?
Es ist offensichtlich, dass hier ein Betrug vorliegt.
david
*lol* Verschwörungstheorie *lol*
wenn der Kurs nicht das macht was ihr euch wünscht sind immer andere drann schuld.....
bei freerealtime seht ihr ja nur einen Kurs (1xBid/1xAsk), an der OTC kann aber jeder Handeln der ne Lizenz hat....lest selbst
http://www.otcbb.com/asp/mp_quotes.asp?Quotes=CALY
MPID Bid Size Ask Size U O/C
SLKC 0.2 5000 0.27 5000 Closed best !!!!
SCHB 0.2 5000 0.25 5000 Closed best !!!!
HRZG 0.195 5000 0.26 5000 Closed
NITE 0.195 5000 0.24 5000 Closed
MHMY 0.18 5000 0.25 5000 Closed
FRAN 0.18 5000 0.21 5000 Closed best !!!!
FLTT 0.17 5000 0.295 5000 Closed
GVRC 0.16 5000 0.215 5000 Closed
HILL 0.15 5000 0.25 5000 Closed
NATL 0.15 5000 0.3 5000 Closed
OGRU 0.14 5000 0.27 5000 Closed
PGON 0.1 5000 0.51 2500 Closed
WIEN 0.1 5000 0.35 5000 Closed
LTCO 0.09 5000 0.25 5000 Closed
VFIN 0.07 5000 0.285 5000 Closed
ALEX 0.05 5000 0.345 5000 Closed
GROW 0.02 5000 0.35 5000 Closed
LCAM 0.01 5000 1.01 500 Closed
wenn der Kurs nicht das macht was ihr euch wünscht sind immer andere drann schuld.....
bei freerealtime seht ihr ja nur einen Kurs (1xBid/1xAsk), an der OTC kann aber jeder Handeln der ne Lizenz hat....lest selbst
http://www.otcbb.com/asp/mp_quotes.asp?Quotes=CALY
MPID Bid Size Ask Size U O/C
SLKC 0.2 5000 0.27 5000 Closed best !!!!
SCHB 0.2 5000 0.25 5000 Closed best !!!!
HRZG 0.195 5000 0.26 5000 Closed
NITE 0.195 5000 0.24 5000 Closed
MHMY 0.18 5000 0.25 5000 Closed
FRAN 0.18 5000 0.21 5000 Closed best !!!!
FLTT 0.17 5000 0.295 5000 Closed
GVRC 0.16 5000 0.215 5000 Closed
HILL 0.15 5000 0.25 5000 Closed
NATL 0.15 5000 0.3 5000 Closed
OGRU 0.14 5000 0.27 5000 Closed
PGON 0.1 5000 0.51 2500 Closed
WIEN 0.1 5000 0.35 5000 Closed
LTCO 0.09 5000 0.25 5000 Closed
VFIN 0.07 5000 0.285 5000 Closed
ALEX 0.05 5000 0.345 5000 Closed
GROW 0.02 5000 0.35 5000 Closed
LCAM 0.01 5000 1.01 500 Closed
Cool bleiben,
schaut mal auf die Tiefststände.
Dann wisst ihr, wann Grund zur Nervosität angesagt ist.
Ich finde, das sieht garnicht mal so schlecht aus.
schaut mal auf die Tiefststände.
Dann wisst ihr, wann Grund zur Nervosität angesagt ist.
Ich finde, das sieht garnicht mal so schlecht aus.
@2Bombi
Ich hab das alles ausgependelt-ist schon ok.
Ist auch nicht schlimm, wenn du dich erst wieder meldest, wenn der Kurs mit 100 Stk. auf 0,22 $ oder 0,21 § geordert werden sollte.
Gruß Boersenkraehe
@Börsenkraehe
es waren mehr als 100, darf ich nu wieder ???
Ich hab das alles ausgependelt-ist schon ok.
Ist auch nicht schlimm, wenn du dich erst wieder meldest, wenn der Kurs mit 100 Stk. auf 0,22 $ oder 0,21 § geordert werden sollte.
Gruß Boersenkraehe
@Börsenkraehe
es waren mehr als 100, darf ich nu wieder ???
Manche haben die Sache mit dem BID und ASK
anscheinend immer noch nicht verstanden.
Wenn hier einer schreibt:
Ich bekomme nichts am Bid, der sollte sich
in die Ecke stellen und mal still über sich
und sein Hobby nachdenken.
Sorry, mußte sein.
mfg Mars
anscheinend immer noch nicht verstanden.
Wenn hier einer schreibt:
Ich bekomme nichts am Bid, der sollte sich
in die Ecke stellen und mal still über sich
und sein Hobby nachdenken.
Sorry, mußte sein.
mfg Mars
Hallo Caly-Jünger,
rumpelt ganz schön in der OTC-Bude bei Caly. Markante Umsätze seit `ner halben Stunde im Bereich 0,23-,235.
Man solte es einfach erfreut zur Kenntnis nehmen. Logik ist bei dem Kursverlauf `eh nicht mehr zu erkennen.
Bestes Beispiel war nun mal gestern die nette Nachricht über die brasilianische Studie mit Lobeshymnen über CALY.
In Deutschland fast Kaufhysterie bis OTC-Eröffnung und in USA sackt CALY bei jämmerlichen Umsätzen ab.
Lotterie könnte nicht besser sein.
So long,
Mattek
rumpelt ganz schön in der OTC-Bude bei Caly. Markante Umsätze seit `ner halben Stunde im Bereich 0,23-,235.
Man solte es einfach erfreut zur Kenntnis nehmen. Logik ist bei dem Kursverlauf `eh nicht mehr zu erkennen.
Bestes Beispiel war nun mal gestern die nette Nachricht über die brasilianische Studie mit Lobeshymnen über CALY.
In Deutschland fast Kaufhysterie bis OTC-Eröffnung und in USA sackt CALY bei jämmerlichen Umsätzen ab.
Lotterie könnte nicht besser sein.
So long,
Mattek
mars ich habs schon 300 mal versucht zu erklären
ich gebe es auf
andy
bitte ein BID
ich gebe es auf
andy
bitte ein BID
Erstmal freue ich mich über den Kursverlauf in meiner Abwesenheit.
@nihilnovum
Falls du auf mich anspielst,daß musst du mir mal erklären.
Also nochmal kurz ein Beispiel ,der Kurs steht so wie jetzt o,22 zu 0,24,ich gebe eine Order rein zu 0,23 ,es gehen welche für 0,22 über den Tisch und sogar für 0,215 und dann noch für 0,21 ,ich bekomme keine.
Was habe ich jetzt nicht verstanden?
Ausser das die MM`s ,laut Consors ,nicht verpflichtet sind mir welche zuverkaufen.
Bitte klär mich dummen Menschen auf.
Gruß Taboa
@nihilnovum
Falls du auf mich anspielst,daß musst du mir mal erklären.
Also nochmal kurz ein Beispiel ,der Kurs steht so wie jetzt o,22 zu 0,24,ich gebe eine Order rein zu 0,23 ,es gehen welche für 0,22 über den Tisch und sogar für 0,215 und dann noch für 0,21 ,ich bekomme keine.
Was habe ich jetzt nicht verstanden?
Ausser das die MM`s ,laut Consors ,nicht verpflichtet sind mir welche zuverkaufen.
Bitte klär mich dummen Menschen auf.
Gruß Taboa
@nihilnovum u. liebemachtblind
Ausserdem sollte man das mit dem Bid u. Ask nicht verallgemeinern.Wie das sonst so läuft ist mir ja einigermaßen klar,aber an der OTC ist es anders .
Ich bin nun mal nicht an der OTC geboren und deshalb seid so nett und klärt mich auf.
Gruß Taboa
Ausserdem sollte man das mit dem Bid u. Ask nicht verallgemeinern.Wie das sonst so läuft ist mir ja einigermaßen klar,aber an der OTC ist es anders .
Ich bin nun mal nicht an der OTC geboren und deshalb seid so nett und klärt mich auf.
Gruß Taboa
Für dich entscheidend ist allein das ASK. Was am Bid passiert,kann dir egal sein,außer,du willst verkaufen.
Der MM kann das BID z.B. 30% unter das ASK ziehen und
selbst kaufen,kaufen,kaufen.Daher kommt dein beobachtes Volumen.Deine Kauforder bleibt aber liegen,sofern du sie nicht auf das Ask erhöhst.Gelegentlich bekommst du auch Aktien unter dem Ask-Kurs,ist aber eher selten.Bei hohen Volumina passiert es öfter.
Was die Consors Aussage betrifft: Falls er dich
zum Ask-Kurs nicht bedienen sollte,dann sollte sich
Consors schnell nach einem anderen MM in den USA
umschauen.
mfg Nihil
Der MM kann das BID z.B. 30% unter das ASK ziehen und
selbst kaufen,kaufen,kaufen.Daher kommt dein beobachtes Volumen.Deine Kauforder bleibt aber liegen,sofern du sie nicht auf das Ask erhöhst.Gelegentlich bekommst du auch Aktien unter dem Ask-Kurs,ist aber eher selten.Bei hohen Volumina passiert es öfter.
Was die Consors Aussage betrifft: Falls er dich
zum Ask-Kurs nicht bedienen sollte,dann sollte sich
Consors schnell nach einem anderen MM in den USA
umschauen.
mfg Nihil
@nihilnovum
Danke
Also muss man sich damit abfinden ,daß es Glück ist wenn man welche unterm ASK kriegt.
War nur sehr verwundert.
Darf ich jetzt meinem Hobby weiter nachkommen.
Gruß Taboa
Danke
Also muss man sich damit abfinden ,daß es Glück ist wenn man welche unterm ASK kriegt.
War nur sehr verwundert.
Darf ich jetzt meinem Hobby weiter nachkommen.
Gruß Taboa
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 207 | ||
| 109 | ||
| 71 | ||
| 67 | ||
| 48 | ||
| 39 | ||
| 37 | ||
| 33 | ||
| 30 | ||
| 30 |
| Wertpapier | Beiträge | |
|---|---|---|
| 29 | ||
| 27 | ||
| 24 | ||
| 21 | ||
| 20 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 |
